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Abstract 
Podocytes are critical for establishing the selective permeability of the glomerular 
filtration barrier. Sustained rennin-angiotensin system activation is crucial in the 
pathogenesis of podocyte injury and proteinuria. Mechanisms of angiotensin II (Ang 
II) modulating actin cytoskeletal dynamics of podocytes in physiological or injurious 
stimuli remain unclear. This work demonstrated increased expression of Rac-1 and 
phosphorylated ezrin/radixin/moesin (ERM) proteins in cultured mouse podocytes 
stably expressing Ang II type 1 receptor (AT1R) and in glomeruli of AT1R transgenic 
rats (Neph-hAT1 TGRs). In mouse podocytes, Ang II caused a reactive oxygen 
species (ROS)–dependent rearrangement of cortical F-actin, stress fiber attenuation 
and a migratory phenotype switch. Ang II–induced actin cytoskeletal remodeling was 
provoked by activated Rac-1 and phosphorylated ERM proteins. Phosphorylation of 
ERM proteins may indicate a high actin cytoskeletal turnover state. Heparin, a potent 
G-coupled protein kinase 2 inhibitor, abolished ERM protein phosphorylation in Ang 
II-treated podocytes. However, inhibition of Rho kinase, p38 MAPK or protein kinase 
C had no effect on phosphorylation. The free radical scavenger DMTU abolished Ang 
II–induced cell migration, ERM protein phosphorylation and cortical F-actin ring 
formation, suggesting that ROS mediates the effect of Rac-1 in podocyte AT1R 
signaling. Proteomic analysis of AT1R podocytes revealed Ang II suppressed 
expression of peroxiredoxin 2 (Prx2), an anti-oxidative protein. SiRNA experiments 
targeting Prx2 in cultured podocytes demonstrated that Prx2 is a cellular redox 
reaction modulator. Decreased Prx2 expression in podocytes favors an oxidative 
cellular environment. Moreover, Ang II signaling triggered a down-regulation of α 
actinin-4 and decreased focal adhesion expression in podocytes. The Ang II–induced 
phenotype shift from dynamically stable to adaptively migratory may eventually 
exhaust podocytes with a high actin cytoskeletal turnover, leading to podocyte 
depletion and focal segmental glomerulosclerosis. 
Table of Contents 
 
1.  Introduction..............................................................................................................1 
1.1.  The kidney, Nephron and Glomerular Filtration ...........................................1 
1.2.  Podocyte and Slit Diaphragm........................................................................3 
1.3.  Actin Cytoskeleton of Podocyte....................................................................4 
1.4.  Focal Segmental Glomerulosclerosis (FSGS) ...............................................6 
1.4.1. Pathological Features ...........................................................................6 
1.4.2. Pathophysiological Mechanisms..........................................................6 
1.4.3. Recent Findings for FSGS Pathogenesis .............................................8 
1.4.4. Podocyte Cytoskeleton and FSGS .......................................................8 
1.5.  Renin-Angiotensin System............................................................................9 
1.5.1. Enzymatic Cascade of the RAS and Angiotensin II ............................9 
1.5.2. The Type 1 Angiotensin (AT1) Receptor ...........................................10 
1.5.3. Renal Protective Effects of RAS Blockage .......................................12 
1.5.4. The AT1 Receptors in Podocytes .......................................................12 
1.6.  Rac-1 ...........................................................................................................13 
1.7.  Ezrin/radixin/moesin ERM proteins............................................................14 
1.8.  Alpha actinin-4 ............................................................................................16 
1.9.  Nephrin........................................................................................................18 
1.10. Peroxiredoxin 2 ...........................................................................................19 
1.11. Principal Objectives of this Work................................................................21 
 
2.  Materials ................................................................................................................23 
2.1.  Equipment ...................................................................................................23 
2.2.  Chemicals and Laboratory Requirements ...................................................25 
2.3.  Buffers and Solutions ..................................................................................27 
2.4.  Medium .......................................................................................................30 
2.4.1. Medium for Bacterial Culture............................................................30 
2.4.2. LB Medium (Luria-Bertani Medium)................................................30 
2.4.2.1.  SOB Medium .........................................................................31 
2.4.2.2.  SOC Medium .........................................................................31 
2.4.3. Medium for Eukaryotic Cell Culture .................................................31 
2.5.  Consumptive Materials and Commercial Kits ............................................32 
2.6.  Enzymes ......................................................................................................33 
2.7.  Antibodies ...................................................................................................34 
2.8.  Bacteria........................................................................................................35 
2.9.  Eukaryotic cells ...........................................................................................36 
2.10. Oligonucleotides..........................................................................................36 
2.11. Software and Internet Program....................................................................37 
2.12. Plasmid Construct Maps..............................................................................39 
 
3.  Methods..................................................................................................................44 
3.1.  Molecular Cloning Methods........................................................................44 
3.1.1. Amplification of Double–Strand DNA by PCR.................................44 
3.1.2. Reverse transcription PCR.................................................................46 
3.2.  Cellular Biologic Methods ..........................................................................47 
3.2.1. Cell Culture........................................................................................47 
3.2.2. Calcium Phosphate Transfection........................................................48 
3.2.3. Retroviral Gene Delivery...................................................................49 
3.2.4. Intracellular Calcium Measurement...................................................51 
3.2.5. Measuring NADPH Oxidase Activity and Superoxide Generation...51 
3.2.6. In Vitro Wound Healing (‘scratch’) Assay.........................................52 
3.2.7. Life Cell Imaging...............................................................................52 
3.2.8. Cellular ROS Determination..............................................................53 
3.3.  Protein Biochemistry Methods ....................................................................53 
3.3.1. Immunoprecipitation and Western Blotting.......................................53 
3.3.2. Two-dimensional electrophoresis followed by immunoblotting .......55 
3.3.3. Animal Tissue Preparations ...............................................................56 
3.4.  Immunofluorecent Stainings .......................................................................56 
3.4.1. Cultured Cells and Cortical F-actin Score Index ...............................57 
3.4.2. Cryosectioned Human Kidney Tissues ..............................................58 
3.4.2.1.  Tissue Preparation and Storage ..............................................58 
3.4.2.2.  Thin-Sectioning of Renal Tissue (Fresh Cryosections) .........58 
3.4.2.3.  Indirect Double-Staining Method ..........................................59 
3.5.  2-D DIGE System and Proteomics..............................................................60 
3.5.1. 2-D Electrophoresis and DIGE ..........................................................60 
3.5.2. Methods for 2-D DIGE and Proteomic Analysis ...............................62 
3.6.  Gene Silencing ............................................................................................64 
3.6.1. Mechanisms of RNA Interference .....................................................64 
3.6.2. Vector-Based SiRNA .........................................................................67 
3.6.3. Retroviral SiRNA Vector ...................................................................67 
3.6.4. Cloning SiRNA Insert into pRNA Vectors.........................................68 
3.6.5. Producing Retroviral Particles and Infecting Cells............................69 
3.7.  Statistical Analysis.......................................................................................69 
 
4.  Results....................................................................................................................70 
4.1.  Establishment and Characterization of a Stable Ang II-Responsive Podocyte 
cell line ........................................................................................................70 
4.2.  Increased Rac-1 Expression in Cultured AT1R Podocytes and in Glomeruli 
of Neph-hAT1 TGRs ...................................................................................73 
4.3.  Effects of Ang II on ROS Generation and Migration in Podocytes ............74 
4.4.  Characterization and Quantification of Rac-1-Mediated Podocyte 
Cytoskeletal Reorganization in AT1R Signaling.........................................75 
4.5.  Rac-1 mediates Ang II–induced ERM protein phosphorylation .................78 
4.6.  Alpha actinin-4 is down-regulated in Neph-hAT1 TGR glomeruli and Ang 
II–treated cultured podocytes ......................................................................82 
4.7.  Slit Diaphragm Protein—Nephrin is Down-Regulated in AT1R signaling.85 
4.8.  Proteomics of Ang II–treated podocytes .....................................................87 
4.9.  Peroxiredoxin 2 is Down-Regulated in AT1R signaling .............................89 
4.10. Decreased Prx2 Expression Also Causes Oxidative-Mediated ERM protein 
phosphorylated in Podocytes.......................................................................91 
 
5.  Discussion..............................................................................................................94 
5.1.  Establishing an In Vitro Model to Explore AT1R Signaling in Podocytes ..94 
5.2.  The Vital Physiological and Pathophysiological Roles of Actin Cytoskeleton 
in Podocytes and Filtration Barrier .............................................................95 
5.3.  Rac-1 Orchestrates AT1R Signaling on Podocyte Cytoskeletons via ROS 
Formation ....................................................................................................97 
5.4.  “Rac and Rho” of AT1R Signaling in Podocytes? ......................................99 
5.5.  “PKC-independent Rac Activation” of AT1R Signaling in Podocytes .....100 
5.6.  Effects of Ang II–induced ROS on the Podocyte Cytoskeleton................102 
5.7.  Effects of AT1R-induced Cytoskeleton Reorganization on the Apical 
Membrane Domain of FPs ........................................................................103 
5.8.  Effects of AT1R Induced Cytoskeleton Reorganization on FP Basal 
Membrane Domain....................................................................................105 
5.9.  Effects of AT1R Induced Cytoskeleton Reorganization on the SD Domain of 
FPs .............................................................................................................106 
5.10. AT1R Signaling Down-regulates Peroxiredoxin 2 in Podocytes—“RedOx 
Switching” .................................................................................................107 
 
6.  Conclusion ...........................................................................................................109 
7.  Prospect................................................................................................................112 
8.  Appendix..............................................................................................................114 
9.  Reference .............................................................................................................117 
10. Acknowledgements..............................................................................................130 
11. Curriculum Vitae..................................................................................................131 
 
 
INTRODUCTION 
1 
 
1. Introduction 
 
1.1. The kidney, Nephron and Glomerular Filtration 
 
The kidneys perform their most important function by “clearing” unwanted 
substances from blood and excreting these substances in the urine while returning 
needed substances back to the blood. The ability of the kidney to perform many of its 
functions depends on the three fundamental functions—filtration, reabsorption, and 
secretion. Each human kidney is made up of approximately 1 million nephrons, each 
capable of generating urine. Figure 1.1.1 displays the embryonic development and 
functional parts of a nephron. Each nephron is composed of a tuft of glomerular 
capillaries called the glomerulus, through which substantial amounts of fluid are 
filtered from the blood (filtration), a capsule around the glomerulus called Bowman’s 
capsule, and a long tubule in which filtered fluid is converted into urine on its way to 
the renal pelvis (reabsorption and secretion), which receives urine from all nephrons. 
 
 
 
Fig. 1.1.1 Embryonic development and anatomy of kidney (a) The metanephros develops from 
reciprocal interactions between the mesonephric duct (giving rise to the ureter) and metanephric 
mesenchyme at the caudal end of the nephrogenic cord. At embryonic stage E11.5, the ureter has 
invaded and branched once in the mesenchyme. (b) Nephrons are continuously induced at the ureter 
tips and undergo a well-defined series of morphological transformations: first, condensation of 
mesenchymal cells; second, mesenchymal-to-epithelial transition with formation of the renal vesicle; 
third, the comma-shaped body transformation; fourth, the S-shaped body transformation with invasion 
of endothelial cells; and, fifth, formation of the glomerulus and patterning of the nephron into its 
segments. (c) Anatomy of an adult kidney and nephron position and arrangement. Schedl A. Nature 
Reviews Genetics, 2007 
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The glomerulus is a ball of capillaries surrounded by the Bowman’s capsule, a hollow 
capsule of the tubular epithelium through which urine is filtered. The glomerulus also 
contains mesangial cells, which comprise a scaffold supporting capillary loops and 
have contractile and phagocytic characteristics. Blood enters the glomerular 
capillaries through an afferent arteriole and exits via an efferent arteriole rather than 
venule. Vasoconstriction of this efferent arteriole generates high hydrostatic pressure 
in the glomerular capillary, forcing water, iron, and small molecules through the 
filtration barrier into Bowman’s capsule. Whether a substance is filtered depends on 
both its molecular size and charge (Fig. 1.1.2). 
 
 
 
Fig. 1.1.2 The glomerular filtration barrier Blood enters glomerular capillaries and is filtered across 
the endothelium and glomerular basement membrane, and through the filtration slits between podocyte 
foot processes to generate the urine filtrate. In healthy glomeruli, this barrier restricts the passage of 
macromolecules (e.g. albumin). Ronco P J. Clin. Invest. 2007 
 
 
The filtration barrier has three layers: Endothelial cells. The endothelial cells of the 
glomerular capillary wall are thin, with many 70 nm pores filled with negatively 
charged glycoproteins—mostly podocalyxin. Glomerular basement membrane. This 
membrane is a specialized capillary basement membrane that also contains negatively 
charged glycoproteins. This basement membrane has two layers, comprised of type IV 
collagen, heparin sulfate proteoglycans, laminin, podocalyxin and low levels of type 
III and V collagen, fibronectin, and entactin. The type IV collagen forms helical 
strands arranged into a three-dimensional framework on to which other components 
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are attached. Epithelial cells. The epithelial cells or so-called podocytes have long 
projections from which foot processes arise and attach to the urinary side of the 
glomerular basement membrane. Foot processes from differentiated podocytes 
interdigitate, leaving filtration slits 25–65 nm in diameter between foot processes 
from adjacent podocytes. Across these slits, a highly organized network of several 
glycoproteins forms ‘slit pores’ through which filtration occurs and which prevent the 
passage of large molecules such as albumin. 
 
1.2. Podocyte and Slit Diaphragm 
 
Podocytes have a significant role in generating selective permeability of the 
glomerular filtration barrier. Podocyte injury can cause proteinuria, a sign of 
glomerular diseases.1 Differentiated podocytes are mesenchymal-like cells that arise 
from epithelial precursors during renal development. These differentiated podocytes 
consist of three morphologically and functionally different segments: a cell body (CB); 
major processes (MPs); and, foot processes (FPs). Major processes arise from the CB 
and split into FPs. Podocyte FPs comprise a highly branched interdigitating network 
with FPs of neighboring podocytes connected by the slit diaphragm (SD), which is a 
multiprotein complex similar to adheren junctions and covers filtration slits (regions 
between opposing podocyte FPs), thereby establishing the final barrier to urinary 
protein loss (Fig. 1.2). 
 
Slit diaphragm-interconnected FPs cover the exterior basement membrane surface of 
the glomerular capillary, stabilize glomerular architecture by counteracting 
distensions of the glomerular basement membrane,2 and maintain a large filtration 
surface through the SDs.3 Thus, SD-interconnected FPs are responsible for 
approximately 40% of filtration barrier hydraulic resistance. The contractile structures 
of podocyte foot processes typically respond to vasoactive hormones and thereby 
modulate the ultrafiltration coefficient Kf.2;4 Podocytes contribute to specific size and 
charge characteristics of the glomerular filtration barrier, and podocyte damage results 
in retraction of their FPs and proteinuria.5;6 Podocytes are the injury target of many 
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glomerular diseases. Podocyte cell shape changes, such as retraction of FPs and even 
podocyte loss, occur in minimal-change nephropathy, membranous nephropathy, focal 
segmental glomerulosclerosis, chronic glomerulonephritis, and diabetic 
nephropathy.7-11 Despite decades of research, the physiological and molecular 
mechanisms of glomerular filtration and its disturbances remain unclear. 
 
 
 
Fig. 1.2 Podocyte and slit diaphragm (a) Glomerular endothelial cells (E) embracing the capillary 
lumen (CL) and mesangial cells (M) are located on the blood side of the glomerular basement 
membrane (GBM), whereas podocytes cover the outer aspect of the GBM facing Bowman’s space (BS). 
(b) Scanning electron microscopy illustrates the complexity of podocyte morphology. Podocytes 
consist of a cell body (CB), major processes (MPs) and foot processes (FPs). Only FPs directly contact 
the GBM. They also interdigitate with FPs of neighboring cells and form filtration slits (shown in (c), 
interposed slit diaphragms (SDs) cover the filtration slits). Faul et al. Trends Cell Biol. 2007 
 
 
1.3. Actin Cytoskeleton of Podocyte 
 
Podocytes function is largely based on their complex cell architecture, and, in 
particular, on the maintenance of the normal FP structure. FPs contain an actin-based 
cytoskeleton linked to the GBM in focal contacts (the basal membrane domain 
(BMD), also known as sole plate). These FPs are further characterized by a cortical 
network of short branched actin filaments (the apical membrane domain (AMD)), and 
the presence of highly ordered, parallel, contractile actin filament bundles,4 which are 
believed to modulate filtration barrier SD permeability through changes in FP 
morphology. All three domains—AMD, BMD and SD—are physically and 
INTRODUCTION 
5 
 
functionally linked to the actin cytoskeleton (Fig. 1.3); thus, actin is the common 
denominator in podocyte function and dysfunction.12 Interference with any of these 
three FP domains transforms the actin cytoskeletons arising from parallel contractile 
bundles into a dense network with FP effacement (reflected by the simplification of 
the FP structure and loss of normal interdigitating pattern) and proteinuria. Foot 
process effacement requires active reorganization of actin filaments.13-15 Therefore, 
proteins regulating the plasticity of the podocyte actin cytoskeleton are extremely 
important for maintenance of glomerular filter function. 
 
 
 
Fig. 1.3 All three foot process domains are physically and functionally linked to the actin 
cytoskeleton of podocytes (a) This schematic displays the connections between the cortical actin 
cytoskeleton, slit diaphragm, and components of the podocyte basolateral portion. The membrane 
domains are marked: apical cell membrane domain (green); SD domain (blue); and, “sole” of the FP 
(pink). (b) The origin of several FPs from a MP. The cytoskeleton of MPs predominantly consists of 
microtubules and intermediate filaments. The FPs contain bundles of parallel actin filaments (arrows) 
that connect neighboring FPs. (c) At high magnification (×65000), the well-organized parallel actin 
bundles (arrows) are clearly visible. (d) Top view of normal and effaced podocyte FPs. (i) In healthy 
podocytes, FPs regularly interdigitate. The highly organized actin bundles of interdigitating FPs from 
two adjacent podocytes are in red and yellow, respectively. Microtubules of MPs are blue. (ii) In 
effaced podocytes, a meandering cell border exists between effaced FPs. A continuous sheet of 
cytoplasm develops that is filled with reorganized, short, branched actin filaments (green). Modified 
from Ronco P J. Clin. Invest. 2007 and Faul et al. Trends Cell Biol. 2007 
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1.4. Focal Segmental Glomerulosclerosis (FSGS) 
 
Focal and segmental glomerulosclerosis (FSGS) is a very common primary 
glomerular disease that terminates as end-stage renal disease (ESRD).16;17 In most 
series, the ten-year survival rate is 40–60%.18-21 
 
1.4.1. Pathological Features 
 
Focal and segmental glomerulosclerosis is a pattern of injury defined by a segmental 
scar, which involves only some glomeruli. The classic scar is defined by a segmental 
scar located either at the capillary hilum or in the glomerular periphery (Fig. 1.4.1 a). 
The scar comprises either obliteration of glomerular architecture and replacement by 
collagen or segmental glomerular collapse (Fig. 1.4.1 b). The overlying parietal and 
visceral epithelium may be prominent, especially when associated with an adhesion. 
This lesion is frequently associated with hyalinosis and adhesions. Detailed 
morphological analysis in rodents largely corresponds to that for human pathology, 
and demonstrates that this disease entity is a result of a primary dysfunction of the 
podocyte (‘podocytopathy’) (Fig. 1.4.1 c). 
 
1.4.2. Pathophysiological Mechanisms 
 
Severe damage to podocytes by numerous damaging mechanisms results in a local 
loss of the separation between the tuft and Bowman’s capsule.10 This happens 
affixation of either parietal epithelial cells (PECs) to the glomerular basement 
membrane (characteristic of degenerative mechanisms such as hypertension or direct 
toxic effects to podocytes) or affixation of podocytes to the parietal basement 
membrane (characteristic of inflammatory diseases such as anti-GBM nephritis). This 
adhesion develops either into a proteinaceous crescent based on misdirected filtration 
common in degenerative diseases,22-24 or into a cellular or mixed crescent, which are 
generally associated with inflammatory diseases.25-27 The progression of both 
crescents may stop by evolving into an adherent segmental scar (synechia)—the 
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hallmark of segmental glomerulosclerosis. Conversely, a crescent may progress to 
global sclerosis and finally cause nephron degeneration and fibrosis.26 
 
 
Fig. 1.4.1 Pathology, pathophysiology and factors involved in the progression of FSGS to ESRD 
(a) Typical features of classic form FSGS (periodic acid-Schiff stain): A segmental scar with an 
adhesion to Bowman’s capsule (white arrow) and hyalinosis is present in the perihilar region of the 
glomerulus. Hilar arteriole (∗). (b) The sclerotic lesion (scar) is characterized by focally increased 
matrix within the glomerular tuft with obliteration of the glomerular capillary lumen. Intraglomerular 
scar impairs normal filtration function resulting in renal insufficiency. (c) Initial loss or injuries to 
podocytes (related to hereditary factors, increased glomerular pressure (Pgc), reduced podocyte 
numbers, defects in membrane proteins or cytoskeletal instability) leads to cytokine release, 
mechanical stress, hyperfiltration, and glomerular hypertrophy. These factors result in up-regulation of 
an inflammatory response. The end result is collagen matrix deposition, fibrosis and progression to 
ESRD. Modified from Shankland SJ Kidney Int. 2006; Reidy K and Kaskel FJ Pediatr Nephrol. 2007 
and Chun et al. J Am Soc Nephrol. 2004. 
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1.4.3. Recent Findings for FSGS Pathogenesis 
 
Strong mechanistic evidence indicating that podocyte depletion is the central 
mechanism in FSGS development has been established by targeting damage directly 
and specifically to podocytes; no study of FSGS-induced by damage targeted to 
parietal epithelial, endothelial or mesangial cells has been presented. The notion that 
the inability of podocytes to replicate cells is the initial cause of glomerular diseases 
dates to the early 1990s.28;29 Detailed descriptive and correlative evidence has since 
been provided in numerous studies demonstrating that severe damage to podocytes 
follows a loss of podocytes, which underlies the development of classic FSGS.26 
Recently, two studies—a study of rats by Wiggins,30 and a study of mice by 
Ichikawa31-33—clearly demonstrated that the degree of podocyte depletion predicts 
sclerosis severity. Both studies utilized transgenic rodents, and specifically addressed 
damage to podocytes. Notably, glomerulosclerosis in these rodent models did not start 
before the number of podocytes declined, and, thus, started after the onset of podocyte 
lesions and proteinuria. 
 
1.4.4. Podocyte Cytoskeleton and FSGS 
 
Gene mutations associated with podocyte development and function have taken center 
stage in hereditary glomerular diseases. Two basic groups of diseases can be identified: 
those with early onset, indicating that lesions have already occurred in fetal or 
neonatal life; and, those with late onset. Late onset diseases typically emerge 
predominantly due to impaired function of the podocyte cytoskeleton, whereas early 
onset diseases are rooted in severe structural deficiencies of various components 
(GBM and slit membrane) or defects in major signaling networks for development 
and maintenance.34 Notably, α actinin-4 and synaptopodin are actin–associated 
proteins with specific relevance for actin bundling in podocytes. Mutations in the α 
actinin-4 gene in humans lead to an autosomal dominant form of familial late onset 
FSGS (see Introduction, Section 1.8 Alpha actinin-4).35;36 
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1.5. Renin-Angiotensin System 
 
The renin-angiotensin system (RAS) has a significant homeostatic role in blood 
pressure regulation, water and salt balance, and tissue growth control under 
physiological conditions. Conversely, the involvement of the RAS in the 
pathophysiology of cardiovascular and renal diseases is supported by basic and 
clinical data. In particular, angiotensin II (Ang II), the biological effector of the RAS, 
can induce a number of relevant structural and functional abnormalities via activation 
of numerous cellular effects primarily mediated via Ang II binding with type 1 
angiotensin (AT1) subtype receptors. Through the binding of Ang II with specific G 
protein–coupled receptors present on the cellular membranes of numerous tissues, 
Ang II is the terminal biological effector of the RAS and is responsible for important 
and diverse functions that have fundamental relevance in human physiology and 
pathology.37;38 
 
1.5.1. Enzymatic Cascade of the RAS and Angiotensin II 
 
The RAS is typically viewed as an enzymatic proteic cascade, which, through the 
generation of intermediate peptidic products, finally leads to production of Ang II, a 
small octapeptide. Ang II has a central role in regulation of cardiovascular 
homeostasis (Fig. 1.5.1). Acting on both the “content” and “container,” Ang II 
regulates blood volume and vascular resistance. The wide spectrum of Ang II target 
tissues encompasses the adrenals, kidney, brain, pituitary gland, vascular smooth 
muscle, and sympathetic nervous system. Angiotensin is a blood-borne hormone that 
is produced by enzymatic cleavage of angiotensinogen and acts in circulation, and is 
formed in many tissues such as the brain, kidney, heart, and blood vessels. Thus, 
researchers have suggested that Ang II may also function as a paracrine and autocrine 
hormone that induces cell growth and proliferation and controls extracellular matrix 
formation.39-41 Other angiotensin-derived metabolites, such as angiotensin 2–8 (Ang 
III), angiotensin 1–7, or angiotensin 3–8 (Ang IV), have biological activities (Fig. 
1.5.1 b).42-46 
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Fig. 1.5.1 Renin-angiotensin system (a) Diagram of the conventional renin-Ang II pathway with its 
receptors and general biological effects (b) Amino acid sequences of Ang II precursors and 
metabolites. 
 
 
1.5.2. The Type 1 Angiotensin (AT1) Receptor 
 
The human type 1 angiotensin (AT1) receptor contains 359 amino acids;38 its 
sequence is reported in the SwissProt file under No. 30556 (P30556); the gene coding 
for the receptor (abbreviated as AGTR1) is located on chromosome 3q. Similarly, the 
structural coding for rat and mouse AT1 receptors is (rat) 359 amino acids, P29089, 
P25095 and (mouse) 359 amino acids, P29754, P29755 as two subtypes A and B exist 
in rats and mice located on chromosomes 17 and 2, and 13 and 3, respectively. 
 
Figure 1.5.2 presents the secondary structure and consensus sequence of the 
mammalian angiotensin AT1 receptor. The amino acid sequence shown is based on 
derived sequences for five individual cloned mammalian AT1 receptors. The amino 
acid residues that are highly conserved among G protein-coupled receptors are 
indicated by bold letters. The positions of the three extracellular carbohydrate chains 
and two extracellular disulfide bonds are also indicated. 
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Fig. 1.5.2 Secondary structure and consensus sequence of the mammalian angiotensin AT1 
receptor The amino acid sequence shown is based on derived sequences for five individual cloned 
mammalian AT1 receptors. The amino acid residues that are highly conserved among G 
protein-coupled receptors are indicated by bolded letters. The positions of the three extracellular 
carbohydrate chains, and two extracellular disulfide bonds are also indicated. de Gasparo et al. 
Pharmacol Rev. 2000 
 
 
The AT1 receptor mediates all known physiological actions of Ang II in 
cardiovascular, renal, neuronal, endocrine, hepatic, and other target cells. These 
actions comprise regulation of arterial blood pressure, electrolyte and water balance, 
thirst, hormone secretion, and renal function. The AT1 receptor belongs to the G 
protein-coupled receptor (GPCR) superfamily and is predominantly coupled via 
pertussis toxin-insensitive G proteins to activate phospholipase C and calcium 
signaling. The AT1 receptors of several mammalian species have been cloned and 
their amino acid sequences identified from their respective cDNAs. Ang II binding to 
the AT1 receptor causes conformational change in the receptor molecule, thereby 
promoting the receptor’s interaction with the G protein(s), which in turn mediates 
signal transduction via several plasma membrane effector systems. These systems 
include enzymes, such as phospholipase C, phospholipase D, phospholipase A2, and 
adenylyl cyclase, and ion channels such as L-type and T-type voltage-sensitive 
calcium channels. In addition to activating several intracellular signaling pathways 
that mediate agonist-induced phenotypic responses in various Ang II target cells, the 
agonist-occupied AT1 receptor undergoes desensitization and internalization in the 
same manner as many other GPCRs. 
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1.5.3. Renal Protective Effects of RAS Blockage 
 
The RAS blockage with angiotensin-converting enzyme inhibitors (ACEIs) or AT1R 
antagonists (AT1RBs) were primarily conceived for treating hypertension. Reduction 
of Ang II levels by ACEIs or AT1RBs is renoprotective in human glomerular diseases, 
especially in diabetic nephropathy.47-49 The RAS blockage decreases proteinuria and 
moderates reduction in glomerular filtration rate in human diseases and experimental 
animal models.50-54 The beneficial anti-proteinuric effects of ACEIs and AT1RBs have 
been partially explained by their hemodynamic effects on the glomerulus. 
Nevertheless, increasing clinical and experimental data demonstrate that Ang II 
targets influence and damage podocytes directly and specifically. 
 
1.5.4. The AT1 Receptors in Podocytes 
 
Within the glomerulus, Ang II was thought to influence preferentially mesangial cell 
function. However, experimental and clinical data has indicated that AT1RBs 
ameliorate glomerular function, and, in contrast to other antihypertensive agents, 
decrease podocyte hypertrophy in rat kidneys following subtotal nephrectomy,55 
implying that podocyte morphology can be directly impacted by Ang II. In literatures, 
convincing evidence indicates that Ang II directly regulates podocyte function.49;56;57 
It has been demonstrated that Ang II depolarized podocytes ex vivo with a patch 
clamp technique of isolate intact rat glomerulus.58 Fluorescence measurements with a 
laser scanning microscope indicated that podocytes in glomerulus responded to Ang II 
with a reversible increase of intracellular calcium.59 Moreover, podocyte-specific 
overexpression of AT1R is suggestive of considerable involvement when the RAS in 
FSGS development is due to hypertension.60 Rats (Neph-hAT1 transgenic rats (TGRs)) 
with podocyte-specific enhanced AT1–mediated signaling developed proteinuria and 
glomerular damage that progressed to FSGS mimicking the structural details 
identified in hypertensive models of FSGS development.61 These studies support a 
conclusion that beneficial effects of ACEIs or AT1RBs slow progression of chronic 
disease—in addition to their beneficial effects in lowering blood pressure—stem from 
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prevention of increased AT1R signaling in podocytes. 
 
1.6. Rac-1 
 
The mammalian Rho guanosine-5'-triphosphate hydrolase (GTPase) family currently 
consists of seven distinct proteins: Rho (A, B, and C isoforms), Rac (1 and 2 
isoforms), Cdc42 (Cdc42Hs and G25K isoforms), RhoD, RhoG, RhoE, and TC10. 
Like other members of the Ras superfamily, Rho proteins act as molecular switches 
that control cellular processes by cycling between active GTP-bound and inactive 
GDP-bound states. 
 
During cell migration, Rho family GTPases organize the actin cytoskeleton in all 
eukaryotic cells.62 Activation of Rho in fibroblasts causes bundling of actin filaments 
into stress fibers, and clustering of integrins and associated proteins into focal 
adhesion complexes; activation of Rac promotes de novo actin polymerization at the 
cell periphery to form lamellipodia extensions and membrane ruffles; activation of 
Cdc42 triggers actin polymerization to form filopodia or microspikes (Fig. 1.6). 
Considerable crosstalk exists within and between Ras and Rho GTPase families. 
Activation of Cdc42 results in localized activation of Rac, and, hence, filopodia are 
closely associated with lamellipodia; in fact, in these cells, identifying filopodia 
unless Rac activity is first inhibited is difficult. Quiescent Swiss cells have no 
detectable stress fiber, and activation of Rac under these conditions results in a weak 
and delayed activation of Rho, thereby producing only a few weak stress fibers. 
However, activation of Rac in cells growing in serum, which already have very 
pronounced and abundant stress fibers, results in a loss of stress fibers. 
 
Notably, Rac-1 exhibits a ubiquitous expression pattern and is a crucial component of 
Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, which mediates 
Ang II–induced ROS production.63-65 Furthermore, very recent experimental data 
demonstrate that Rho GTPases (RhoA and Rac) have different involvements in 
cytoskeletal effects of Ang II in rat adrenal glomerulosa cells.66 This work investigates 
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the effects of Rac-1 on podocyte cytoskeletons in AT1R signaling. 
 
 
 
Fig. 1.6 The activation of Rho, Rac, and Cdc42 by extracellular agonists induces changes to actin 
cytoskeletons and cell-matrix interaction In these cells, lysophosphatidic acid (LPA, a major 
constituent of tissue culture serum) activates Rho, leading to assembly of actin-myosin stress fibers and 
associated integrin adhesion complexes (focal adhesions). Notably, Rac can be activated by 
Platelet-derived growth factor (PDGF) or by insulin, thus leading to actin polymerization at the cell 
periphery, causing lamellipodia extensions and membrane ruffling activity. Lamellipodia, also 
associated with integrin adhesion complexes, contain many of the same constituents as classical focal 
adhesions, but are markedly smaller. Lamellipodia are not required for actin polymerization, but may 
be required for cell movement. Bradykinin induces Cdc42 in these cells to generate filopodia or 
microspikes and associated integrin complexes. Mackey et al. J Biol Chem. 1998 
 
 
1.7. Ezrin/radixin/moesin ERM proteins 
 
Ezrin, discovered 20 years ago, is a major component of the microvillus cytoskeleton 
and the chicken intestinal cell brush border.67 Recent studies determined that ezrin 
together with radixin and moesin68;69 define a family of closely related proteins (ezrin, 
radixin and moesin (ERM) proteins) that can potentially link actin microfilaments to 
the plasma membrane. Since this pioneering work, ERM proteins have been 
implicated in myriad cellular functions, ranging from regulation of cell extension to 
polarity, migration and growth.70 
 
Understanding the functions of ERM proteins has become important to human health 
as ezrin is now recognized as a primary regulator of tumor metastasis.71;72 Initial 
attempts to inactivate ERM proteins in cultured cells utilized antisense nucleotides or 
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laser-assisted inactivation methods, and demonstrated that ERM proteins are involved 
in control of cell shape and adhesive characteristics.73;74 
 
The ERM proteins have three structural domains: the N-terminal domain (major 
functional domains, N-ERMAD); a coiled midregion; and, the C-terminal domain 
(C-ERMAD). The N-ERMAD domain of ERM protein interacts with an increasing 
number of integral membrane proteins, such as I-Cam, CD44, CD43 and Nhe3.70 
Additionally, the N-ERMAD domain interacts with adaptor proteins (EBP50 or 
NHE-RF,75 and NHE type 3 kinase A regulatory protein (E3KARP)70) and is involved 
in signal transduction. The C-ERMAD domain of the ERM protein binds to actin 
filaments. 
 
Furthermore, the N- and C-ERMAD domains, which are connected by a flexible 
α-helical region, are also capable of intramolecular interaction.76 As this 
N-ERMAD–C-ERMAD interaction masks the two regions involved in binding to 
membrane proteins and F-actin,77;78 this hairpin-like intramolecular interaction results 
in a closed or dormant configuration of ERM proteins. The ERM proteins therefore 
must be activated to generate an open conformation,79 enabling these proteins to 
interact with their heterotypic partners (Fig. 1.7). Although the mechanism is not fully 
understood, activation of ERM proteins involves both binding of phosphatidylinositol 
(4,5)-bisphosphate [PtdIns(4,5)P2] to N-ERMAD domain,80;81 and phosphorylation of 
a threonine residue of the F-actin-binding domain, which is located at the C 
terminus.82 
 
Ezrin has recently been identified as a part of podocyte actin cytoskeleton, and little is 
known about its functional characteristics.83-85 As mentioned, small GTP-binding 
proteins of the Rho family integrate extracellular signals from diverse receptor types 
and initiate rearrangements of F-actin. Activation of Rho GTPases induces actin 
polymerization by increasing the availability of actin filament barbed ends. However, 
the induced spatial pattern of F-actin depends on associated actin-binding proteins or 
cross-linking proteins such as ezrin and α actinin-4 (see Introduction, Section 1.8 
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Alpha actinin-4). This study investigates the factors that regulate these processes, and 
how these factors may in turn respond to messages from the Rho family GTPases. 
 
 
 
Fig. 1.7 Schematic representation of ERM protein structures and activation The intramolecular 
interaction between N-ERMAD (FERM) and C-ERMAD (cylinder) keeps ERM proteins in a dormant 
configuration in cytoplasm. Upon activation via binding of phosphatidylinositol (4,5)-bisphosphate 
[PtdIns(4,5)P2] and phosphorylation of a conserved threonine residue of C-ERMAD, ERM proteins 
switch to an open configuration unmasking protein-binding regions. The FERM domain binds directly, 
or through a PDZ adaptor, to membrane proteins, whereas the C-terminal region of ERM proteins binds 
to actin filaments. Polesello et al. Trends Cell Biol. 2004 
 
 
1.8. Alpha actinin-4 
 
Alpha actinin is a ubiquitously expressed protein that is regarded as the ancestral 
molecule within a family of actin-binding proteins that includes spectrin, dystrophin, 
and utrophin, each of which regulates the organization of the actin cytoskeleton in a 
cell-type-specific manner.86 The α actinin is a rod-shaped antiparallel dimer of two 
100-kDa monomers; this configuration positions its actin-binding calponin homology 
(CH) motifs at either end of the rigid rod, an arrangement that allows α actinin to 
efficiently cross-link actin filaments into tight bundles.87;88 
 
In skeletal and cardiac muscle, α actinin is found in the Z disk, where it cross-links 
antiparallel actin filaments from adjacent sarcomeres (Fig. 1.8a). Interactions between 
α actinin and titin likely play a role in controlling Z disk assembly.89;90 In nonmuscle 
cells, α actinin is a ubiquitously expressed cytoskeletal protein and  cross-links actin 
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filaments at sites of cell-cell (adhesion junctions) and cell-matrix (focal adhesion) 
junctions (Fig. 1.8 b), and at the leading edges (focal complex) of cell membranes of 
migrating cells. 
 
 
Fig. 1.8 Function of α actinin in the sarcomeric Z disk and in focal contacts (a) In the muscle Z 
disk, α actinin cross-links antiparallel actin filaments from adjacent sarcomeres. Titin acts as a 
molecular ruler for sarcomere and interacts with two different parts of α actinin, at the center of the α 
actinin rod and with the calmodulin-like domain. (b) A simplified representation of a focal contact 
displaying α actinin linking the actin cytoskeleton to membrane-associated structures. Focal contacts 
are points where cultured cells are attached tightly to the extracellular matrix via transmembrane 
receptors such as integrins (α and β). α actinin has been shown to interact with β integrins and with 
focal contact components vinculin and zyxin. Thus, α actinin may connect integrins to actin filaments 
either directly or indirectly. Djinović-Carugo et al. Cell 1999 (αA: α actinin) 
 
 
In podocytes, α actinin-4 is encoded by the FSGS gene ACTN4,35 which serves as an 
actin-binding and cross-linking protein localized to podocytes in the renal glomerulus, 
predominantly in FPs. In vitro, FSGS-associated mutations increase the strength of α 
actinin-4 binding to actin filaments.91 The same effect can be expected in vivo, and 
results in alteration of glomerular podocyte mechanical characteristics. Recently, a 
experimental study showed that α actinin-4 null mice have severe glomerular 
disease,91 and α actinin-4 is required for normal podocyte adhesion.92  
 
Little is known about the effects of α actinin-4 on Ang II–related actin cytoskeletal 
change in podocytes. This work examined the function of α actinin-4 in AT1R 
signaling and the associated mechanisms leading to FSGS in Neph-hAT1 TGRs. 
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1.9. Nephrin 
 
Nephrin, the product of the gene NPHS1 mutated in congenital nephrotic syndrome 
(NS) of the Finnish type (CNF), was the first podocyte protein identified by research 
into hereditary NS. Notably, CNF is common in Finnish people and has also been 
identified in various ethnic groups wourldwide.93 CNF develops in utero causing 
premature infants with low birth weights for their age. Severe NS is frequently present 
at birth and resistant to steroids and immunosuppressive drugs.93;94 Before the 
development of adequate treatments, patients typically died of various complications 
within the first 6 months of life.94 
 
Using the positional cloning, Kestilä et al. identified a new gene on chromosome 19 
called NPHS1 that is mutated in CNF.95 Nephrin, the gene product, is a 
transmembrane protein of the Ig family of cell adhesion molecules that is located at 
the podocyte SD.96 Inactivation of Nphs1 in mice results in massive proteinuria, 
effacement of podocyte FPs, absence of SDs, and neonatal death.97 These effects 
suggest that nephrin is a primary component of the glomerular filter. Protein 
tomography data from the Tryggvason group suggest that nephrin molecules from 
adjacent podocytes connect via their Ig-like extracellular domains and form 
zipper-like structures, according to the SD model developed by Rodewald and 
Karnovsky (Fig. 1.9).98 
 
Unlike α actinin-4, which links actin filaments to the GBM in focal contacts (the basal 
membrane domain) and cross-links the parallel actin bundles in the apical membrane 
domain of the podocyte FPs, nephrin connects the SD to the actin cytoskeleton in 
FPs.99;100 The SD is formed by extracellular domains of specific transmembrane 
proteins, such as nephrin, Neph proteins, and two large cadherins, FAT1 and FAT2. 
Intracellularly, proteins important to podocyte structure—ZO-1, podocin, and 
CD2AP—are located in the SD region and are believed to play a role in connection of 
the SD to actin microfilaments.101 
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Fig. 1.9 Nephrin and slit diaphragm (a) and (b) The slit diaphragm (SD) structure proposed by 
Rodewald and Karnovsky in 1974. A central filament is connected to the podocyte membranes by 
alternating bridge fibers. This view is in the direction of filtrate flow. (c) (Top panel) Podocytes cover 
the outside wall of glomerular capillaries and extend primary processes attached to the surface of the 
glomerular basement membrane. Secondary FPs extend from the primary processes to interdigitate 
with FPs of a neighboring podocyte. The slit between the FPs contains a thin porous filter called the SD. 
(Bottom panel) Prior to formation of FPs and the SD, prepodocytes covering glomerular capillaries are 
connected via tight junctions. During formation of FPs, nephrin (N) becomes phosphorylated (P), likely 
upon contact with its extracellular ligand, resulting in recruitment of Nck adaptor proteins and 
induction of actin polymerization. Once the SD is assembled, the nephrin molecules are 
dephosphorylated and nephrin is connected to actin through CD2AP, podocin (Pc), and possibly other 
proteins. Following injury to the SD, which leads to FP effacement and proteinuria, nephrin molecules 
become clustered, thereby inducing their phosphorylation, Nck association, and actin polymerization. 
Finally, upon injury repair, nephrin molecules are dephosphorylated and the SD-actin filament complex 
is restored as in normal mature FPs. Modified from Rodewald R and Karnovsky MJ J. Cell Biol. 1974 
and Tryggvason et al. Cell 2006 
 
 
One important question is whether cytoskeletal dysregulation of podocytes has 
pathological consequences for the structure/function of the SD and filtration barrier? 
This study therefore analyzes the impact of AT1R signaling on nephrin. 
 
1.10. Peroxiredoxin 2 
 
Organisms living under aerobic conditions develop various anti-oxidative mechanisms 
for protection from damage by reactive oxygen species (ROS) such as hydrogen 
peroxide and superoxide.102 A novel family of antioxidative proteins, peroxiredoxin 
(Prx), was identified 20 years ago and currently comprises six members in 
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mammals.103-105 Prxs share a common reactive cystine residue in the N-terminal region, 
and serve as a peroxidase and involve thioredoxin and/or glutathione as the electron 
donor. Prxs protect against oxidative damage in cells via their peroxidase activity 
(ROOH + 2e− →  ROH + H2O), whereby hydrogen peroxide, peroxynitrite and 
numerous organic hydroperoxides (ROOH) are reduced and detoxified. (Fig. 1.10) 
 
 
 
Fig. 1.10 The catalytic cycle of 2-Cys peroxiredoxin (Prx) Peroxidatic cysteine is depicted as a thiol 
(SPH), sulfenic acid (SPOH), sulfinic acid (SPO2H), or in a disulfide with resolving cysteine (SRH). 
Colors differentiate the cysteines from different dimer subunits, and the striped bar is the intersubunit 
disulfide bond. The disulfide reductase varies with organisms, typically a thioredoxin or flavoenzyme 
containing a thioredoxin-like domain. Wood et al. Science 2003. 
 
 
Among the six isoforms (Table 1.10), Prx1 to Prx4 have an additional cystine residue 
in the conserved C-terminal region, and are cross members as determined by amino 
acid sequence similarity. Notably, Prx5 also contains an additional cystine in its 
C-terminal region, which is less conserved than that of Prx1–4. Conversely, Prx6 has 
only 1 unique cystine. These Prx family members are distributed in cytosol, 
mitochondria, peroxisome and plasma, all of which are potential sites of ROS 
production. In addition to their roles as a peroxidase, however, a growing body of 
evidence suggests that individual family members also have different functions 
associated with various biological processes such as detoxification of oxidants, cell 
proliferation, differentiation and gene expression. 
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Table 1.10 Six isoforms of the peroxiredoxin family Peroxiredoxins (Prxs) are divided into three 
classes: typical 2-Cys Prxs; atypical 2-Cys Prxs; and 1-Cys Prxs. Although varying in cellular location 
and interacting protein partners, all Prxs share the same basic catalytic mechanism. Wood et al. Trends 
Biochem Sci. 2003 
 
Recent experimental data suggest that Prxs regulate peroxide-mediated signaling 
cascades. In vivo, Prxs are required for Myc-mediated transformation and apoptosis,106 
can regulate NF-κB activation,107;108 and their overexpression can decrease 
intracellular hydrogen peroxide generated in response to tumor necrosis factor-α, p53, 
epidermal growth factor, and thyrotropin.109;110 Additionally, overexpression of Prxs is 
common in several cancers and is correlated with resistance to apoptosis induced by 
radiation therapy or the anticancer drug cisplatin.111;112 However, the function of Prx2 
in podocytes has never been investigated. 
 
 
1.11. Principal Objectives of this Work 
 
Little is known about the signaling mechanisms of AT1R in podocytes, particularly 
because no reliable cultured podocyte model functionally expressing AT1R exists. 
Furthermore, the mechanisms resulting in dynamic change of the actin cytoskeleton in 
podocytes are poorly understood. This study therefore investigates the mechanisms of 
Ang II–mediated regulation of actin cytoskeletal organization in podocytes and has the 
following aims. 
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? Establishing a stable Ang II-responsive podocyte cell line 
 
? Identify effectors and effects of AT1R signaling in cultured podocytes 
 
? Functional characterization of AT1R signaling in podocytes 
 
? Confirm signal mechanisms in vivo — in Neph-hAT1 TGRs 
 
? Proteomic analysis of AT1R-activated cultured podocytes 
 
? Lose of function studies—SiRNA technique in cultured podocytes 
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2. Materials 
 
2.1. Equipment 
 
Equipment Name Type and Number Supplier 
Autoclave Varioklav H+P Labortechnik GmbH 
Bioluminescence detecting 
system 
Lumat LB9501 Berthold 
Bacterial culture incubator B5050 Heraeus 
Bacterial incubator shaker Certomat® IS B.Braun Biotech International 
Chemiluminescent signal 
analyzer 
Lumi-Imager F1 Roche 
Centrifuges Mikro 200 R 
Allegra TM X-22R 
Multifuge 3S-R 
Hettich 
Beckman 
Heraeus 
Cell culture incubator Heracell 240 Heraeus 
Digital electronic balance ScoutTMPro 
Explorer®Pro 
OHAUS 
DIGE fluorescent gel image 
system 
Typhoon 9200 GE Healthcare 
Electroporesis apparatus 
(vertical) 
Criterion® 3 Cell Bio-Rad 
Electroporesis apparatus 
(PAA gel) 
Novex Mini-Cell Invitrogen 
Electroporesis apparatus 
(agarose gel) 
Model B1 Peqlab Biotechnologie GmbH 
Film developer Optimax X-Ray 
Film Processor 
PROTEC Medizintechnik 
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Equipment Name Type and Number Supplier 
Isoelectric Focusing Cell PROTEAN IEF cell Bio-Rad 
Lamina flow hood for cell 
culture 
HERAsafe Heraeus 
Luminance detector Lumat LB9501 Berthold GmbH 
Microscope for 
immunoflurescence 
AXIOVERT 100 Zeiss 
Microscope for life cell 
imaging 
AXIOVERT 25 Zeiss 
Microscope for intracellular 
calcium measurement 
AXIOVERT 125 Zeiss 
PCR thermal cyclers GeneAmp® 
PCR-System 2700 
Applied Biosystems 
pH-meter RS-232-C Schott 
Photometer Smart Spec TM Bio-Rad 
Power supply for blotting and 
electrophoresis 
Power Pac HCTM Bio-Rad 
Thermomixer Comfort Eppendorf 
Ultra pure water system Ultra Clear SG Wasseraufbereitung und 
Regenerierstation GmbH 
UV transilluminator IL-200-M H. Saur Laborbedarf  
D-Reutlingen 
Video camera XC-ST70C  Hamatsu/Sony 
Vortexer VortexGenie2 Scientific Industries, Inc. N.Y. 
USA 
Western-Blot apparatus Semidry 
Transfercell 
Bio-Rad 
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2.2. Chemicals and Laboratory Requirements 
 
Material Name Brand/Supplier 
1 kb DNA ladder Promega 
100 bp DNA ladder Promega 
2-Propanol Roth 
6 x Loading Dye Solution MBI Fermentas 
β-Mercaptoethanol (β-ME) Sigma-Aldrich 
Acetic acid Roth 
Agarose Roth 
Ammonium Chloride Roth 
Ammonium Persulfate (APS) Sigma-Aldrich 
Bio-Lyte 3/10 Ampholyte, 100x Bio-Rad 
Bromphenolblue Bio-Rad 
Calcium Chloride Sigma-Aldrich 
Calcium gluconate Sigma-Aldrich 
Calphostin C (Pan PKC inhibitor) Calbiochem 
Coomassie brilliant blue R-250 Sigma-Aldrich 
CHAPS Sigma-Aldrich 
Crystal Clear Mounting Medium Sigma-Aldrich 
D-glucose monohydrate AppliChem 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
Dithio-1,4-threitol (DTT) Sigma-Aldrich 
Dimethylthiourea (DMTU) Sigma-Aldrich 
Ethanol Roth 
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Material Name Brand/Supplier 
Ethidium bromide AppliChem 
Ethylenediamine tetraacetic acid (EDTA) Omnilab 
Ethylene glycol tetraacetic acid (EGTA) Sigma-Aldrich 
Fura-2-acetomethyl ester Molecular Probe 
Geniticin (G418) PAA 
Glycerin (Glycerol) Roth 
Glycin Roth 
HCl (37 %) Roth 
Hydrogen Peroxide (H2O2) 30 % Sigma-Aldrich 
Iodoacetamide Sigma-Aldrich 
KH2PO4, potassium dihydrogen phosphate Sigma-Aldrich 
K2HPO4, dipotassium phosphate Sigma-Aldrich 
LB-Broth Powder Sigma-Aldrich 
Lucigenin Sigma-Aldrich 
Losartan (AT1R specific antagonist) Merck & Co. 
Magnesium Chloride Sigma-Aldrich 
Methanol Roth 
N, N, N´, N´-Tetramethylendiamin (TEMED) Fluka 
NaCl, sodium chloride Fluka 
NaH2PO4, sodium dihydrogen phosphate Fluka 
NaDS, sodium dodecyl sulfate (SDS) AppliChem 
NaF, sodium fluoride Sigma-Aldrich 
Na3VO4, sodium orthovanadate Sigma-Aldrich 
Paraformaldehyde (PFA) Fluka 
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Material Name Brand/Supplier 
PD123319 (AT2R specific antagonist) Sigma-Aldrich 
PEG 4000 Roth 
PMSF AppliChem 
Ponceau S solution Sigma-Aldrich 
Polybrene Sigma-Aldrich 
Polyester seiving net, Ø100 µm und Ø51 µm Reichelt Chemietechnik, 
Heidelberg 
Precision Plus Protein Dual Colour Standard BioRad 
SB203580 (p38 MAPK inhibitor) Calbiochem 
SCH51344 (Rac specific inhibitor) Calbiochem 
Tris(hydroxymethyl)aminomethan (Tris, Trizma® 
Base) 
Sigma-Aldrich 
Triton® X-100 Sigma-Aldrich 
Thiourea Sigma-Aldrich 
Trypsin GE Healthcare 
Urea Sigma-Aldrich 
Xanthine and xanthine oxidase Sigma-Aldrich 
Y27632 (Rho kinase specific inhibitor) Calbiochem 
 
 
2.3. Buffers and Solutions 
 
Solution Name Contents and Supplier 
1 x PBS  Dulbecco´s Phosphate buffered Saline with or 
without Ca2+ & Mg2+, PAA 
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Solution Name Contents and Supplier 
2 x HEBS HEPES acid 10 g, NaCl 16 g, KCl 0.74 g, 
Na2HPO4 x H2O 0.25 g, glucose 2 g, 10 ml 10x 
PBS, add H2O to 1 litre, adjust pH to 7.05, sterile 
by filtering and stored in -20°C 
2DE lysis buffer 7 M Urea, 2 M Thiourea, 4% CHAPS, and 30 
mM Tris) 
2DE 2X sample buffer 7 M urea, 2 M Thiourea, 4% CHAPS, 100 mM 
dithiothreitol (DTT) and 8% IPG buffer (Bio-Lyte 
3-10) 
2DE equilibrating buffer I 37.5 mM Tris-HCl (pH 8.8), 6 M urea, 20% 
glycerol, 2% SDS, and 1% DTT 
2DE equilibrating buffer II 37.5 mM Tris-HCl (pH 8.8), 6 M urea, 20% 
glycerol, 2% SDS, 0.002% bromophenol blue, 
and 2.5% iodoacetamide 
Acrylamide solution 40 % acrylamide/bis-acrylamide Solution, 
Bio-Rad, 4°C 
Calcium Chloride solution 0.25 M 
Column buffer 200 mM NaCl, 20 mM Tris/HCl [pH 7.4], 1 mM 
EDTA, 4°C 
Collagen A 1 mg/ml Biochrom, 4°C 
Coomassie ready-use solution Coomassie stock solution with H2O 1:10 dilution 
Coomassie stock solution 0.6 % (w/v) Coomassie brilliant blue, 10 % acetic 
acid in H2O 
Coomassie gel destaining 
solution (Destaining Solution) 
5-20 % methanol, 7 % acetic acid in H2O 
KREBS solution 99 mM NaCl, 4.7 mM KCl, 1.8 mM CaCl2, 1.2 
mM MgCl2, 25 mM NaHCO3, 1.03 mM K2HPO4, 
20 mM Na-HEPES, and 11.1 mM glucose (pH 
7.35] 
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Solution Name Contents and Supplier 
Fixing Solution for Coomassie 25 % isopropanol, 10 % acetic acid in H2O 
Fixing Solution for SyproRuby 10 % methanol, 7 % acetic acid in H2O 
Hepes 1M PAA, 4°C (long-term storage -20°C) 
Interferon γ Roche, -20°C 
IP-buffer ready-use solution IP-buffer stock solution + 0.25 mM PMSF (in 
EtOH) + 5 mM Na3VO4, fresh make before use 
IP-buffer stock solution 1 % Triton X-100, 20 mM Tris/HCl [pH 7.5], 25 
mM NaCl, 50 mM NaF, 15 mM EDTA, 4°C 
KERBS solution 99 mM NaCl, 4.7 mM KCl, 1.8 mM CaCl2, 1.2 
mM MgCl2, 25 mM NaHCO3, 1.03 mM K2HPO4, 
20 mM Na-HEPES, and 11.1 mM glucose [pH 
7.35] 
Laemmli-sample buffer 2 x 20 % (v/v) glycerol, 125 mM Tris/HCl [pH 6.8], 
10 % (w/v) SDS, 0.2 % (w/v) Bromphenolblue, 5 
% (v/v) β-ME in H2O, -20°C 
Na3VO4  
(Tyrosine-Phosphatase-Inhibitor)
100 mM stock solution, Sigma , -20°C 
Paraformaldehyde,(PFA 2 % (w/v) Paraformaldehyde, 4% (w/v) 
Saccharose in 1x PBS, -20°C 
Phenylmethanesulphonylfluoride, 
PMSF 
10mg/ml PMSF in EtOH stock solution, 
AppliChem, -20°C 
Protein-electrophoresis (PAGE) 
buffer 10x, (10x Running buffer) 
2 M glycine, 0.5% (w/v) SDS, 250 mM Tris-Base
Ringer solution  145 mM NaCl, 1.6 mM K2HPO4; 0.4 mM 
KH2PO4; 5 mM D-glucose; 1 mM MgCl2; 1.3 
mM Ca2+-gluconate (pH 7.4) 
STET-buffer 8 % (w/v) Saccharose, 50mM EDTA, 5 % (v/v) 
TritonX-100, 50 mM Tris/HCl [pH 8] 
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Solution Name Contents and Supplier 
TAE-buffer AppliChem 
TBS-T 
(Tris-buffered Saline + Tween) 
10 mM Tris [pH 7.4], 0.05 % Tween-20, 150 mM 
NaCl 
TE Buffer 10 mM Tris [pH 8.0], 1 mM EDTA 
Transfer-buffer 10x 144 g glycine, 30 g Tris-base, add H2O to1 liter 
Transfer-buffer 1x 1/10 10x Transfer-buffer, 10-20% methanol, add 
H2O to 1 liter 
Trypsin-EDTA PAA, ready to use solution stored in 4°C, 
long-term storage in -20°C 
 
 
2.4. Medium 
Unless otherwise stated, sterile medium are stored at 4°C. 
 
2.4.1. Medium for Bacterial Culture 
 
2.4.2. LB Medium (Luria-Bertani Medium) 
Per liter: 
 To 950 ml of deionized water, add 
 trypton     10g 
 yeast extract     5g 
 NaCl     10g 
The solutes were shaken until they dissolved. The pH was adjusted to 7.0 with 5 N 
NaOH. Solution volume was adjusted to 1 liter with deionized water. Solution was 
sterilized by autoclaving for 20 min at 15 psi (1.05 Kg/cm2) on the liquid cycle. 
For antibiotic resistant selection, 100 µg/ml Ampicillin or 35 µg/ml Kanamycin were 
added. Agar plates with LB medium were made by adding an additional 20 g/l 
agarose. 
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2.4.2.1. SOB Medium 
Per liter: 
 To 950 ml of deionized water, add 
 trypton     10g 
 yeast extract     5g 
 NaCl     10g 
Solutes were shaken until dissolved; 10 ml 250 nM solution of KCl was then added. 
Medium pH was adjusted to 7.0 with 5 N NaOH, and solution volume was adjusted to 
1 liter with deionized water. Solution was sterilized by autoclaving for 20 min at 15 psi 
(1.05 Kg/cm2) on the liquid cycle. Just prior to use, 5 ml 2 M MgCl2 was added to 
solution. 
 
2.4.2.2. SOC Medium 
After the SOB medium was autoclaved, it was allowed to cool to 60°C or less, and 20 
ml sterile 1 M solution of glucose was added. 
 
2.4.3. Medium for Eukaryotic Cell Culture 
 
Cell Type Content and Supplier 
Mouse podocyte 
(PCLs) 
RPMI 1640 (PAA) + 5 % FCS (+ 75-300 mg/L Geniticin 418 for 
transducted cells selection)  
Cultivated in 33°C: + 10 U/ml γ-Interferon 
Human podocytes 
(AB8) 
RPMI 1640 (PAA) + 5 % FCS + 0.8 % Supplements 
Supplements 0.1 % non-essential aminoacids(Bio Whittaker) 
100 µM Sodium pyruvate 
10 µg/ml Insulin-Transferrin-Natrium-Selenit (Roche) 
5 mM HEPES 
FCS BioChrom AG 
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Cell Type Content and Supplier 
HEK 293T cells DMEM (+L-Glutamin+high Glucose 4.5 g/l) PAA + 10 % FCS 
(or CS/Fe) 
Type I collagen #C3867, Sigma-Aldrich, 4°C 
 
 
2.5. Consumptive Materials and Commercial Kits 
 
Material Name Supplier 
Advanced Protein Assay™ agents Cytoskeleton 
Alexa Fluor® 594 Phalloidin Molecular Probes 
Alexa Fluor® 488/594 conjugated secondary antibodies Molecular Probes 
Bacterial culture dish / sterile inoculation loop Sarstedt 
BigDye Terminator v1.1 / 3.1 Sequencing Buffer(5x) Applied Biosystems 
Blotting paper Schleicher & Schüll 
Complete protease inhibitor Roche 
Cell / tissue culture dish / flask Greiner 
Cy2,Cy3,Cy5-CyDye DIGE Fluor minimal dyes GE Healthcare 
Coverslides / slide for microscope VWR 
DAPI (4'-6-Diamidino-2-phenylindole) Molecular Probes 
ECL-Film FUJIFILM Super RX 
Flexi-Strip Schaber BiWeX, Tilburg Holland 
LumiLight (chemoluminescencent substrate) Roche Diagnostics 
M2 (anti-Flag antibody-conjugated) beads Sigma-Aldrich 
oligo(dT) primer Promega 
Pipettenspitzen Sarstedt 
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Material Name Supplier 
Plasmid Miniprepkit, Wizard® Plus SV Minipreps Promega 
Protein G–sepharose beads Amersham Biosciences 
PureLinkHiPure Plasmid Filter Maxiprep Kit Invitrogen 
PVDF-Immobilon Membrane (0.45µm) Millipore 
QIAquick Gel Extraction Kit 
QIAquick PCR Purification Kit 
Qiagen 
ReadyStrip™ IPG Strip Bio-Rad 
RNeasy Minikit Qiagen 
Safe-Lock Tubes (“Epp1s”) Eppendorf, Roth 
Sterile filter Millipore 
SyproRuby gel staining solution Bio-Rad 
Vectashield Hard Set™ Axxora 
Centrifuge test tube 15ml / 50ml BD Falcon 
 
 
2.6. Enzymes 
 
Enzyme Name Supplier 
Calf Intestine Alkaline Phosphatase, 1.000 U Promega 
Pfu Turbo DNA Polymerase  Stratagene 
Go Taq DNA Polymerase Promega 
Lysozyme Roth 
M-MLV Reverse Transcriptase Promega 
Phusion High Fidelity DNA-Polymerase Finnzymes 
Proteinase K (PNK) Promega 
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2.7. Antibodies 
 
Specificity IF WB Supplier 
α actinin-4 (#210-356) 1:200 1:2000 Alexis 
β-tubulin (sc-9104) - 1:1000 Santa Cruz 
β-tubulin (TUB 2.1) 1:200 1:2000 AbCam 
AT1R (sc-1173) - 1:1000 Santa Cruz 
AT2R (sc-9040) - 1:500 Santa Cruz 
Actin (sc-1616) - 1:500 Santa Cruz 
Catalase (LF-PA0060) - 1:1000 Ab-Frontier 
ezrin/radixin/moesin (#3142) 1:200 1:2000 Cell signaling 
FLAG (M2) - 1:10000 Sigma-Aldrich 
Focal Adhesion Kinase 1:100 - Cell signaling 
phospho-ezrin(Thr567)/radixin(Thr564) 
/moesin(Thr558) (#3141) 
1:50 1:1000 Cell signaling 
Peroxiredoxin 1 (rabbit, LF-PA0007) - 1:3000 Ab-Frontier 
Peroxiredoxin 2-cys (6E5, LF-MA0073) - 1:1000 Ab-Frontier 
Peroxiredoxin 2 (rabbit, LF-PA0007) - 1:3000 Ab-Frontier 
Enzyme Name Supplier 
RNase A AppliChem 
RNase-Free DNase Promega 
Restriction enzyme (restriction endonuclease) NEB, Promega 
T4 DNA Ligase MBI Fermentas 
T4 Polynucleotide Kinase Promega 
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Specificity IF WB Supplier 
Peroxiredoxin 2 (mouse, LF-MA0071) - 1:1000 Ab-Frontier 
Nephrin (rabbit polyclonal) - 1:1000 Larry Hotzmann 
Nephrin (GP-N1, guinea pig polyclonal) 1:50 1:500 Progen 
Nephrin (GP-N2, guinea pig polyclonal) - 1:500 Progen 
Rac-1 (#610650) 1:100 1:2000 BD Biosciences 
Wilm’s tumor 1 (WT1, 6F-H2) 1:200 - Dako 
Horseradish peroxidase conjugates goat 
anti-rabbit IgG (H+L) 
- 1:500 
~1:2000 
Jackson 
ImmunoResearch
Horseradish peroxidase conjugates goat 
anti-mouse IgG (H+L) 
- 1:500 
~1:3000 
Jackson 
ImmunoResearch
Horseradish peroxidase conjugates 
donkey anti-goat IgG (H+L) 
- 1:500 
~1:2000 
Jackson 
ImmunoResearch
Horseradish peroxidase conjugates goat 
anti-guinea pig IgG 
- 1:1000 Jackson 
ImmunoResearch
 
 
2.8. Bacteria 
 
Species Genotype Supplier 
BL21 F–ompT gal dcm lon hsdSB(rB- mB-) Invitrogen 
DH5α F-Ф80 lacZ∆M15 
∆(lacZYA-argF)U169 deoR recA1 
endA1 hsdR17(rk-, mk+) phoA supE44 
thi-1 gyrA96 relA1 λ- 
Invitrogen 
TOP10 F-mcr A∆ (mrr-hsdRMS-mcrBC) Ф80 
lacZ∆M15 ∆ lacX74 recA1 araD139 
galU galK  ∆(ara-leu)7697 rpsL 
(StrR)endA1 nuG 
Invitrogen 
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2.9. Eukaryotic cells 
 
Cell 
Name 
Description Reference 
HEK 
293T 
Human embryonic kidney cells generated by 
transformation of cultures of normal human 
embryonic kidney cells with sheared adenovirus 5 
DNA. 
Cultured in 37°C, 5% CO2 
ATCC-Nr.CRL-1573
AB8 
cells 
Immortalized cultured human podocytes 
Proliferation culture: 33°C, 5% CO2 Differentiation 
culture: 37°C, 5% CO2 
Saleem et al. 2002 
PCLs Immortalized cultured mouse podocytes 
Proliferation culture: 33°C, 5% CO2 Differentiation 
culture: 38°C, 5% CO2 
Schiwek et al. 2004 
 
 
2.10. Oligonucleotides 
 
Name Sequenz ( 5´→ 3´) 
hAT1R-EcoR-Kozar for cgc ggg gaa ttc gcc acc atg att ctc aac tct tct act gaa gat gg 
hAT1R-Not-Stop-Flag 
rev 
cc cgc ggg gcg gcc gc tta tta ttt gtc gtc atc gtc ttt gta gtc cat 
tca ctc aac ctc aaa aca tgg tgc agg c 
hAT1R-sequence for gtt tgc cag cta taa tcc atc g 
hAT1R-sequence rev cca gca gcc aaa tga tga tgc 
hAT1R+Flag for cca tgt ttt gag gtt gag gca atg gac tac aaa gac g 
hAT1R+Flag rev cgt ctt tgt agt cca ttg cct ca acct caa aac atg g 
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Name Sequenz ( 5´→ 3´) 
hAT1R-RTPCR for caa tga agt ccc gcc ttc gac gc 
hAT1R-RTPCR rev ctt tgt agt cca ttg cct caa cc 
mAT1Ra-RTPCR for cgt cat cta ctt tta cat gaa g 
mAT1Ra-RTPCR rev gcc cag gat gtt ctt ggt tag g 
mAT1Rb-RTPCR for gaa tct cag aac tca aca ctc c 
mAT1Rb-RTPCR rev gtt gat aac cct gca tgc gac c 
mAT2R-RTPCR for gtg caa agt gtt tgg ttc ttt tc 
mAT2R-RTPCR rev cat agt ctc tct ctt gcc ttg ga 
mGAPDH-RTPCR for aac ttt ggc att gtg gaa gg 
mGAPDH-RTPCR rev aca cat tgg ggg tag gaa ca 
ShRNA sequence, sh1 
(sense strend) 
gaa gta cgt ggt cct ctt t 
(target human Prx2 a.a position: 105-124) 
ShRNA sequence, sh2 
(sense strend) 
gaa gta cgt gga cct ctt t 
(target mouse Prx2 a.a position: 105-124) 
ShRNA sequence, sh3 
(sense strend) 
gtg gat gac agc aag gaa t 
(target human and mouse Prx2 a.a position: 559-577) 
 
 
2.11. Software and Internet Program 
 
Software/Program Supplier 
AMIRA TGS Inc., San Diego, CA, USA 
Axiovision 4.2 Zeiss 
HiPic32, Hamatsu Photonics Deutschland GmbH Hersching 
BioEdit sequence alignment editor Ibis Biosciences 
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Software/Program Supplier 
DeCyder™ v6.5 Differential Analysis Software GE Health Life Science 
Blockit RNAi  Invitrogen 
GPS Explorer software Applied Biosystems 
ImageQuant™ TL analysis software GE Health Life Science 
http://jura.wi.mit.edu/bioc/siRNAext/reference.php Whitehead Institut 
http://rsb.info.nih.gov/ij/ Image J 
http://www.expasy.org/   
 
Expert Protein Analysis System, 
Swiss Institute of Bioinformatics
http://www.matrixscience.com/search_intro.html MASCOT 
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2.12. Plasmid Construct Maps 
 
Plasmid:   pCXhAT1S    Original vector: pCXGFP 
Insert:   hAT1-SV40 polyA   Restriction: Eco RI / Bam HI 
Bacterial strain: D5Hα     Antibiotic resistance: Ampicillin 
 
 
Discription: 
A 1.1-kb fragment of the human angiotensin II type 1 receptor (hAT1R) cDNA containing the entire 
coding region (a gift from T. Inagami, Vanderbilt University School of Medicine, Nashville, Tennessee) 
was subcloned to PCR2.1 vector containing a 1.25-kb fragment of the human nephrin promoter 
(NPHS1). A novel transgenic rat (TGR) model with overexpression of the human AT1R in podocytes 
was developed by this 3.5-kb transgene excised with BstXI and BamHI out of the cloning vector to 
study the consequences of an increased AT1 signaling on the structure and function of the glomerular 
filter. 
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Plasmid:  pLXSN.hAT1R.FL.Flag  Original vector: pLXSN 
Insert:   hAT1R.Flag    Restriction:  Eco RI / Not I 
Bacterial strain: D5Hα     Antibiotic resistance: Ampicillin 
 
 
Reference: 
Mann, R., Mulligan, R. C. & Baltimore, D. (1983) Construction of a retrovirus packaging mutant and its 
use to produce helper-free defective retrovirus. Cell 33:153–159. 
 
Discription: 
pLXSN can be used to transfect a packaging cell line and produce retrovirus, which is then collected 
from the supernatant and used to efficiently transduce cells. The target gene is expressed from the 5' 
LTR promoter; neomycin (G418) can be used for antibiotic selection. 
 
Promoter:  5' LTR 
Selection:  prokaryotic—ampicillin  
eukaryotic—neomycin 
Replication: prokaryotic—Col E1  
GenBank Accession No. M28248 
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Plasmid:   pMD.G     Original vector:  pXF3 
Insert:   VSV-G     Restriction: EcoR I / EcoR I 
Bacterial strain: D5Hα     Antibiotic resistance: Ampicillin 
 
 
Reference: 
Miyake K, Suzuki N, Matsuoka H, Tohyama T, Shimada T. (1998) Stable integration of human 
immunodeficiency virus-based retroviral vectors into the chromosomes of nondividing cells. Hum Gene 
Ther 9:467-475. 
 
Discription: 
This vector helps to produce a VSV-G pseudotyped retrovirus with higher transduction efficiency to 
target cells of gene delivery. 
 
Constructed by: Daniel Ory 
Construction date: August 25, 1994 
Comments/References: human CMV promoter is from pBC12/CMV/IL2 (B. Cullen, Cell 46, 1986), 
human beta globin sequence (exons 2 and 3, IVS2, polyA) is from pucMdBs(R)S (gift M. Sadelain). 
VSV G from pSVGL. 
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Plasmid:  pMD.gag/pol     Original vector:  pMD2 
Insert:  gag and pol genes    Restriction: Eco RI / Eco R 
IBacterial strain: D5Hα     Antibiotic resistance: Ampicillin 
 
 
 
Reference: 
Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. (1998) A Third-Generation 
Lentivirus Vector with a Conditional Packaging System. J Virol. 72: 8463–8471 
 
Discription: 
pMD.g/p (pMD.gag/pol) is a packaging construct that contains gag and pol gene. During retrovirus 
assembly, the polyprotein Gag directs protein multimerization, membrane binding, and RNA packaging. 
The pol gene h encodes the reverse transcriptase which is involved in virus integration. 
 
pMDLg/p is a CMV-driven expression plasmid that contains only the gag and pol coding sequences 
from HIV-1. pMDLg/pRRE differs from pMDLg/p by the addition of a 374-bp RRE-containing 
sequence from HIV-1 (HXB2) immediately downstream of the pol coding sequences. 
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Plasmid: pRNA-TH1.4/Retro-mPrdx2/SH1 
Original vector: pRNA-TH1.4/Retro   Restriction: Mlu I / Xho I 
Insert:  short hairpin sequence (for mouse peroxiredoxin 2) 
Bacterial strain: D5Hα     Antibiotic resistance: Ampicillin 
 
 
Reference: 
Yu JY, DeRuiter SL, Turner DL. (2002) RNA interference by expression of short-interfering RNAs and 
hairpin RNAs in mammalian cells. Proc Natl Acad Sci U S A. 99(9):6047-6052. 
 
Discription: 
pRNA-H1.1/Retro siRNA expression vector is compatible with Clontech Retro-X Expression System. 
An H1 promoter drives the siRNA expression with the siRNA insert cloned between Mlu I and Xho 
Isites. The vector contains a hygromycin resistance gene under the control of cytomegalovirus (CMV) 
promoter for establishing stable cell line. The vector uses CMV enhancer/promoter joined MSV 5’LTR 
(CMV/MSV 5'LTR) and MSV 3'LTR for viral transcription and packaging. 
 
Packaging signal: 757-1566 
ColE1 ori: 6456-7342 
SV40 ori & promoter: 6012-6356 
Ampicillin: 7402-8262 
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3. Methods 
 
3.1. Molecular Cloning Methods 
Techniques for DNA manipulations for various purposes are modifications of those in 
“Molecular Cloning: A Laboratory Manual (Third Edition)” by Joseph Sambrook and 
David Russell (Cold Spring Harbor Laboratory Press, 2001). 
 
3.1.1. Amplification of Double–Strand DNA by PCR 
The following procedure was applied to subclone a 1.1-kb fragment of the human Ang 
II type 1 receptor (hAT1R) cDNA containing the entire coding region (a gift from T. 
Inagami, Vanderbilt University School of Medicine, Nashville, TN, USA) was 
subcloned into the retroviral gene delivery vector (pLXSN-hAT1R-Flag). 
 
Oligonucleotide primers complementary to two different regions of the DNA fragment 
of interest were designed. For instance, two oligonucleotide primers were designed for 
hAT1R. 
Primer 1:  5` atg att ctc aac tct tct act gaa gat gg 3` 
Primer 2:  5` tca ctc aac ctc aaa aca tgg tgc agg c 3` 
 
In a 0.2 m1 thin-walled PCR tube on ice, set up a standard reaction by adding the 
following in the order listed: 
5X Amplification buffer (10 µl) 
ddH2O (10 µl) 
Mixture of four dNTPs (1.25 mM each) (8.5 µl) 
Primer 1 (50 to 100 ng) in ddH2O (5 µl) 
Primer 2 (50 to 100 ng) in ddH2O (5 µl) 
dsDNA in TE buffer (100 to 250 ng) (2 µl) 
Phusion High Fidelity DNA-Polymerase (5 units/µ1) (0.5 µl) 
Add H2O to a final volume of 50 µl. 
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Carry out 25–35 cycles of PCR amplification in a PCR machine. The conditions of 
PCR, including primer annealing temperatures, extension times, and number of cycles, 
were optimized. An example of retroviral gene delivery vector (pLXSN-hAT1R-Flag) 
is as follows. 
 
Cycle Denaturation Annealing Polymerization 
First cycle 30 sec at 98°C - - 
Subsequent cycles (2–34) 10 sec at 98°C 30 sec at 60°C 45 sec at 72°C 
Last cycles 10 sec at 98°C 30 sec at 60°C 45 sec at 72°C 
 
Finally, hold at 4°C until the sample is removed. 
 
The purity of the amplified cDNA on an agarose gel was assessed and the fragment of 
interest was eluted by the standard procedures in a QIAquick Gel Extraction Kit. The 
fragment was ligated to an appropriate cloning vector, and an appropriate E. coli host 
was transformed in preparation for minipreps. The ligation reaction was as follows: 
Ligase 10X buffer (2 µl) 
Vector (0.1 pg) 
cDNA inserts (0.5 µg) 
T4 DNA ligase (10 Weiss units) 
Add ddH2O to a final volume of 20 µl. 
The ligation reactions were incubated at 16°C for 12 h before proceeding to 
subcloning. 
 
To identify the correct clones and verify the sequence, mimprep DNA of at least 20 
colonies after E. coli transformation was prepared. These preps were cut with flanking 
restriction enzymes and fragments were run on a 1% agarose gel to identify clones 
with the correct size fragment. The DNA molecules were then directly sequenced by 
combining PCR technology and the dideoxynucleotide chain termination 
method—Cycle Sequencing and Automated Sequencing. The ligation reaction setup 
was as follows. 
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 DNA template (40-800 fmol, 5µl) 
BigDye 3.1 buffer (2 µl) 
BigDye 3.1 mix (2 µl) 
Primer (5 µM, 1 µl) 
Start with the following cycling program: 
 
Cycle Denaturation Annealing Polymerization 
Total 25 cycles 10 sec at 96°C 5 sec at 50°C 4 min at 60°C 
 
The samples were purified for injection and sequence chromatograms were analyzed 
using the BioEdit sequence alignment editor. 
 
3.1.2. Reverse transcription PCR 
Reverse transcription PCR (RT-PCR) is a powerful approach for cDNA cloning and 
gene expression analysis when specific primers are available. Total RNA or mRNA is 
TRY first reverse transcribed into cDNA, which is then amplified by PCR. Briefly, 
specific primers are designed according to conserved nucleic acid motifs in two 
different regions of known genes or their protein products. The primers are annealed 
to the first strand of cDNA synthesized from an mRNA template. Double-stranded 
cDNAs can be generated and amplified using Taq DNA polymerase. 
 
Isolation of total RNA and purification of poly(A)+ RNA from cultured cells were 
performed using standard protocols in the RNeasy Minikit provided by Qiagen. The 
first strand of cDNAs was synthesized from the isolated total RNAs or mRNAs using 
reverse transcriptase and oligo(dT) as a primer. Total RNA (1 pg) or 50 ng mRNA 
template was annealed with 2 µg oligo(dT) primer in a sterile RNasefree 
microcentrifuge tube. Nuclease-free dd H2O was added to a total volume of 15 µl. The 
tube was heated to 70°C for 5 min and allowed to slowly cool to room temperature to 
complete annealing. Briefly, the mixture was spun down to the bottom. First strand 
synthesis was as follows. 
5X M-MLV reverse transcriptase buffer (5 µl) 
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M-MLV reverse transcriptase (1 µl) 
1µg isolated RNA 
dNTPs (10M, 1.25 µl) 
Add H2O to a final volume of 20 µl, incubate at 40°C for 1 h. 
 
The oligonucleic primers were designed based on conserved amino acid sequences in 
two different regions of the specific gene product (protein) of interest. Amplification 
of the specific cDNA of interest was performed by PCR using specific primers. 
 
 
3.2. Cellular Biologic Methods 
Molecular and cellular methods for various purposes are modified versions of those in 
the “Handbook of Molecular and Cellular Methods in Biology and Medicine (Second 
Edition)” by Leland J. Cseke et al., CRC Press, 2003. 
 
3.2.1. Cell Culture 
A recently generated conditionally immortalized mouse podocyte cell line was 
cultivated as reported elsewhere.113 Briefly, podocytes were maintained in Roswell 
Park Memorial Institute (RPMI) 1640 medium (PAA, Cölbe, Germany) supplemented 
with 10% fetal bovine serum (FBS) (Biochrom, Berlin, Germany) in a humidified 
atmosphere of 5% CO2. To stimulate podocyte proliferation, cells were cultivated at 
33°C (permissive conditions). The culture medium was supplemented with 10 U/ml 
mouse recombinant γ-interferon (Roche, Mannheim, Germany) to induce expression 
of the temperature-sensitive large T antigen. To induce differentiation, podocytes were 
maintained at 38°C without γ-interferon (nonpermissive conditions) for at least 2 
weeks. 
 
The HEK293 cells were cultured in Dulbecco/Vogt modified Eagle's minimal essential 
medium (DMEM) (PAA, Cölbe, Germany) supplemented with 10% FBS. For 
immunofluorescence studies and intracellular Ca2+ measurements, podocytes were 
seeded on glass coverslips pre-coated with 0.1 mg/ml mouse collagen (Biochrom, 
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Berlin, Germany) for 30 min at room temperature. 
 
All cells were FBS-deprived for 24 h prior to each experiment. To analyze living cells, 
podocytes were cultivated in a 25-cm² culture flask with plug seal cap (BD Falcon, 
Germany). 
 
3.2.2. Calcium Phosphate Transfection 
The principle of calcium phosphate–mediated transfect ion is that the DNA to be 
transferred is mixed with CaCl2 and phosphate buffer to form a fine calcium phosphate 
precipitation containing the DNA. The precipitate is then placed on a cell monolayer. 
Calcium phosphate precipitate binds/attaches to the plasma membrane and enters the 
cell via endocytosis. This method, which is most widely used for transient and stable 
transfection, was carried out as follows. 
 
Cell monolayers were prepared the day before the transfection experiment. The cell 
monolayers should have 50–70% confluence. The old culture medium was removed 
and cells were fed with 5–10 ml fresh culture medium. 
 
A transfection mixture for each 100 mm dish was prepared as follows: 
2.5 M CaCl2 solution (50 µl) 
Recombinant reporter DNA construct (10 to 30 µg) 
Add ddH2O to a volume of 0.5 ml. 
 
The transfection mixture solution was vortexed well, and then the DNA mixture was 
slowly added dropwise to 0.5 ml of well-suspended 2X Hepes-Buffered Saline (HEBS) 
buffer by continuous mixing by vortexing. The mixture was incubated at room 
temperature for 30–40 min to allow for coprecipitation. 
 
The precipitated mixture was slowly added dropwise to the dish containing the cells 
while the plate was continuously swirled to achieve a good mix. For each 100 mm dish 
containing the cells, 1 ml of the DNA mixture was added. For each 60 mm dish, 0.5 ml 
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of the DNA mixture was added. The plate containing the cells was incubated overnight 
in a 37°C CO2/air (2–5% CO2) incubator. 
 
The medium was removed and the monolayer washed once with 10 ml serum-free 
DMEM medium and once with 10 ml PBS. Fresh culture medium was added and the 
Petri dishes were returned to the incubator. Typically, cells can be harvested 48–72 h 
after transfection for transient transfer analysis. 
 
3.2.3. Retroviral Gene Delivery 
The apical membrane of podocytes is negatively charged due to the presence of 
surface anionic proteins podocalyxin. Subsequently cultured podocytes are resistant to 
conventional methods of transient gene delivery. 
 
Retroviruses can be utilized as effective vectors for gene transfer in mammalian 
systems. Retroviral gene delivery has the following advantages over SV40-based 
plasmid vectors: (1) the retroviral genome can stably integrate into the host 
chromosomes of infected cells and be passed from generation to generation, thereby 
providing an excellent vector for stable transformation; (2) retroviruses have a broad 
infectivity and expression host range for any animal cells via viral particles; (3) 
integration is site specific with respect to the viral genome at long terminal repeats 
(LTRs), which can easily preserve gene structure that remains intact after integration; 
and, (4) viral genomes are very plastic and allow for a high degree of delivered gene 
size manipulation. 
 
Retroviruses, such as Rous sarcoma virus (RSV) and Moloney murine leukemia virus 
(MoMLV), are ribonucleic acid (RNA) viruses that cause a variety of diseases, 
including tumors in humans. These viruses contain two transfer RNA (tRNA) primer 
molecules, two copies of genomic RNA (38S), reverse transcriptase, RNase H, and 
integrase, which are packaged within an envelope. The viral envelope contains 
glycoproteins that determine degree of host infection. When a virus or virion attaches 
itself to a host cell, the viral glycoproteins in the envelope bind to specific receptors in 
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the host cell plasma membrane. The bound complex then facilitates internalization of 
the virus, which loses its coat as it passes through host cell cytoplasm. In the 
cytoplasm, the reverse transcriptase contained in the viral genome catalyzes the 
formation of a double-stranded DNA molecule from the single-stranded viral RNA. 
The DNA molecule circularizes, enters the nucleus, and integrates into host cell 
chromosomes, thereby forming a provirus. Subsequently, the integrated provirus 
functions as a transcriptional template for both messenger RNAs (mRNA) and viral 
genomic RNAs. Such transcription is catalyzed by host RNA polymerase II. The 
mRNAs undergo translation to generate viral proteins and enzymes using host 
machinery. All of these components are packaged in viral core particles. The particles 
move through the cytoplasm, attach to the plasma membrane inner side and bud off. 
This cycle of infection, reverse transcription, transcription, translation, virion assembly, 
and budding is repeated endlessly, thus infecting new host cells. 
 
Retroviruses are single-stranded RNA viruses that can infect a number of organisms, 
including humans and many other mammals. Following infection, the virus genome is 
reversely transcribed into double-stranded DNA, which is integrated into the host 
chromosome via integration mechanisms. The ability to infect target cells, their stable 
replication and high-level gene expression make retroviruses very attractive as gene 
transfer vectors. The retroviral vectors developed in this stuffy proved highly efficient 
for gene delivery and achieved stable long-term expression of transgenes. 
 
Retroviral gene delivery was performed using methods described elsewhere.114 The 
plasmid pLXSN was provided by D. Miller (Fred Hutchinson Cancer Research Center, 
Seattle, WA, USA). The pMD.G and pMD.gag/pol plasmids were gifted by R. 
Mulligan (Harvard Medical School, Boston, MA, USA). A 1.1-kb fragment of human 
Ang II type 1 receptor (hAT1R) cDNA containing the entire coding region (from T. 
Inagami, Vanderbilt University School of Medicine, Nashville, TN, USA) was 
subcloned into the retroviral gene delivery vector using standard cloning techniques 
(pLXSN.hAT1R.FL.Flag). The hAT1R gene-containing virus was produced by 
co-transfecting HEK293 cells with three plasmids (2.5 µg pMD.G, 7.5 µg 
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pMD.gag/pol and 10 µg pLXSN.hAT1R.FL.Flag) using the calcium phosphate method. 
The supernatant was harvested, centrifuged to remove cellular debris and filtered. 
Podocytes cultivated in permissive conditions were infected by virus soup with 8 
µg/ml polybrene and then selected 4 days following viral transduction in geniticin 
(250 µg/ml) to achieve 100% positive cells. 
 
3.2.4. Intracellular Calcium Measurement 
Measurement of cytosolic Ca2+ using Ca2+-sensitive dye and Fura-2-acetomethyl ester 
(Molecular Probes) was performed using an inverted fluorescence microscope.115 
Podocytes were cultivated in collagen-coated coverslips and loaded with 
Fura-2-acetomethyl ester dye (5 µM, 45 min at room temperature). Coverslips were 
then placed into the microscopic chamber with continuous fluid flow. The initial 
superfusing solution was standard Ringer solution (145 mM NaCl, 1.6 mM K2HPO4; 
0.4 mM KH2PO4; 5 mM D-glucose; 1 mM MgCl2; 1.3 mM Ca2+-gluconate [pH 7.4]) 
followed by superfusing with varying Ang II concentrations. 
 
The [Ca2+]i was measured by alternately exciting the dye with a beam at 340 and 380 
nm while monitoring the emission at 530 nm with a single-photon counting tube 
(H3460–04; Hamamatsu, Herrsching, Germany). The Fura-2-acetomethyl ester 
fluorescence signal was calibrated after each experiment using Ca2+ ionophore 
ionomycin (1 µM) and Ringer solutions with the standard Ca2+ concentration or 
without Ca2+. The [Ca2+]i concentration was calculated using the fluorescence ratio of 
340:380 nm and the equation developed by Grynkiewicz et al.116 
 
3.2.5. Measuring NADPH Oxidase Activity and Superoxide Generation 
Podocytes were rinsed twice with ice-cold PBS, scraped with KREBS solution (99 
mM NaCl, 4.7 mM KCl, 1.8 mM CaCl2, 1.2 mM MgCl2, 25 mM NaHCO3, 1.03 mM 
K2HPO4, 20 mM Na-HEPES, and 11.1 mM glucose [pH 7.35]) and centrifuged (200 × 
g, 4°C, 5 min). The supernatant was discarded and the pellet was resuspended in fresh 
KREBS buffer. The cell suspension was added to the KREBS solution containing 5 
µM lucigenin and stimulated with 100 µM NADPH. Bioluminescence was measured 
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using a Lumat LB9501 (Berthold GmbH, Wildbad, Germany). 
 
Cells were subsequently lysed, and protein concentrations were determined using 
Advanced Protein Assay™ agents (Cat.#ADV01, Cytoskeleton, USA). To calculate 
superoxide production, total counts were determined by integrating the area under the 
signal curve by luminescent signal intensity multiplying with time. These values were 
compared with a standard curve generated by xanthine/xanthine oxidase reaction as 
described elsewhere.117 Superoxide generation was expressed as nanomole O2.- 
generated per mg cellular protein per min (nmol O2.-/mg protein/min). Superoxide for 
podocyte stimulation was also generated by the xanthine/xanthine oxidase reaction. 
 
3.2.6. In Vitro Wound Healing (‘scratch’) Assay 
Twelve-well plates were pre-coated with type 1 collagen (#C3867, Sigma-Aldrich), 
and a sufficient number of AT1R podocytes were plated such that they were confluent 
in the wells immediately after differentiation (~14 days). Before creating a scratch 
wound, cells were FBS-starved for 24 h and then treated with Ang II (100 nM) and/or 
other inhibitors (losartan, PD123319, SCH51344, DMTU) for another 24 h. The same 
areas of each well were then displaced by scratching a cross through the layer using a 
pipette tip. Floating cells were removed by washing with PBS. Medium containing 
2.5% FBS was added to the wells and incubated for an additional 48 h. 
 
Images of the scratched areas in each cross wound were photographed at 24 and 48 h 
using an inverted phase-contrast microscope (Axiovert 100, Zeiss, Germany). Three 
independent experiments were performed, and 12 cross wounds were created for each 
group (n = 12). To estimate relative cell migration, the number of cells moving across 
a 1 mm wound border was calculated at 24 and 48 h. 
 
3.2.7. Life Cell Imaging 
Lamellipodium activities and membrane ruffles of individual podocytes were observed 
by time lapse video microscopy, as described elsewhere.118 Twelve hours before 
experiments, the culture medium for differentiated sparsely cultivated podocytes was 
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changed to a vehicle medium (FBS-free and bicarbonate-free RPMI medium at pH 
7.40), and the culture flask caps were sealed. After adding Ang II (final concentration 
of 100 nM) to the vehicle medium, the culture flasks with cells were resealed and 
placed in an electronically controlled heating chamber at 37°C on the stage of an 
inverted phase-contrast microscope (Axiovert 25, Zeiss, Germany). Images were taken 
using time-lapse video recordings at 10-min intervals for 24 h and stored as stacks of 
tiff files. 
 
3.2.8. Cellular ROS Determination 
Intracellular oxidative stress was monitored by measuring changes in fluorescence 
resulting from intracellular probe oxidation. Dihydroethidine (DHE, Molecular Probes, 
USA) enters the cell and is oxidized by ROSs, particularly superoxide, to yield 
fluorescent ethidium. Ethidium binds to DNA (Eth-DNA), further amplifying its 
fluorescence.119 Thus, nuclei are the primary fluorescent structures labeled and 
increases in DHE oxidation to Eth-DNA (i.e., increases in Eth-DNA fluorescence) are 
indicative of superoxide generation. 
 
By simply incubating experimental samples (cryosection of tissues or living cells) in 
the presence of DHE (5 µmol/l, 30–40 min at room temperature) followed by analysis 
of fluorescence allows for rapid and specific detection of intracellular oxidative stress 
due to superoxide anion generation. Dihydroethidium stains the cytoplasm of living 
cells blue (excitation at 370 nm and emission at 420 nm) and chromatin of living cells 
red (excitation at 535 nm and emission at 610 nm). 
 
 
3.3. Protein Biochemistry Methods 
 
3.3.1. Immunoprecipitation and Western Blotting 
Using monoclonal antibodies that specifically recognize Flag-tag (M2 antibody) 
(Sigma-Aldrich), Flag-tagged hAT1R protein expression in cultured podocytes was 
evaluated with immunoprecipitation methods. 
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For immunoprecipitation, cells were washed with ice-cold PBS and homogenized in 
ice-cold lysis buffer (12 mM Tris base, 8 mM HEPES, 50 mM NaCl, 15 mM KCl, 1.5 
mM MgCl2, 1 mM EGTA, 10 mM Na2H2P2O7, 1 mM ATP, 20 mM NaF, 1 mM 
Na3VO4, 1% Triton X-100 and complete protease inhibitor [Roche]) on ice. Lysates 
rested on ice for 30 min and then centrifuged for 1 h at 16000g. Supernatants were 
pre-cleared by incubation with protein G-sepharose beads (Amersham Biosciences) 
coupled with actin antibody (sc-1616, Santa Cruz) for 6 h at 4°C on a rotary wheel. 
The pre-cleared protein extracts were then incubated with anti-Flag 
antibody-conjugated beads (M2 beads) (Sigma-Aldrich) overnight at 4°C on a rotary 
wheel. The M2 beads were then washed twice with lysis buffer without NaF, Na3VO4, 
ATP and Triton X-100. Precipitates were resolved by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis and analyzed by immunoblotting the AT1 
receptor antibody (sc-1173, Santa Cruz). Pre-cleaned protein extracts with equal 
volumes were also resolved by SDS-PAGE and subsequent β-tubulin antibody 
(sc-9104, Santa Cruz) immunoblotting for total protein input control. 
 
For conventional Western blotting, cells or rat kidney tissues were washed with 
ice-cold PBS and homogenized in ice-cold lysis buffer on ice. Lysates were left to rest 
on ice for 30 min and then centrifuged for 1 h at 16000g. Protein concentrations of 
supernatants were measured using Advanced Protein Assay™ agents (Cat.#ADV01, 
Cytoskeleton, USA), and each sample was measured three times to acquire average 
results. Equal amounts of protein extract were resolved by SDS-PAGE and analyzed 
by immunoblotting specific antibodies, followed by subsequent peroxidase-labeled 
secondary antibodies. Chemiluminescent signals (LumiLight, Roche Diagnostics, 
Germany) were detected with a Lumi-Imager and quantified using the LumiAnalyst 
program (Roche Diagnostics, Mannheim, Germany). The entire sodium dodecyl 
sulfate-polyacrylamide gel was subsequently stained with SyproRuby (Bio-Rad, USA) 
for total protein, and quantified and visualized by a Lumi-Imager (300 nm UV 
illumination) to ensure that amounts of protein loaded were approximately equal. 
Chemiluminescent signal intensity detected in each experiment was further 
standardized with total protein staining of a quantity of the representative lane in the 
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quantitative SYPRO Ruby gel-staining method. For each experiment, the matching 
results of SYPRO Ruby gel staining are included in figures containing Western blot 
results (labeled as “loading control”). 
 
3.3.2. Two-dimensional electrophoresis followed by immunoblotting 
Two-dimensional electrophoresis (2DE) was utilized to quantify the expression level 
of the AT1R protein in cultured podocytes with increased sensitivity and specificity. 
Total proteins can be separated by isoelectric point during the first dimension 
electrophoresis, and then separated again by molecular weight in the second dimension 
electrophoresis. Details of 2DE are described in Methods, Section 3.5—2-D DIGE 
System and Proteomics. 
 
Cells were homogenized in 2DE lysis buffer (7 M Urea, 2 M Thiourea, 4% CHAPS, 
and 30 mM Tris) with a micro tissue grinder (model 440630; Radnoti, USA) followed 
by three rounds of sonication (1 min) in an ice bath sonicator at 4°C. Lysates rested on 
ice for 30 min and were then centrifuged for 1 h at 16000g. Supernatant protein 
concentrations were determined as described previously. 
 
For 2DE, 215 µl buffer containing 7 M urea, 2 M Thiourea, 4% CHAPS, 100 mM 
dithiothreitol (DTT) and 8% IPG buffer (Bio-Lyte 3-10, Cat.#163-2094, Bio-Rad, 
USA) were added to each channel in the rehydration tray for overnight rehydration of 
the 11cm IPG Strips, pH 3–10 nonlinear (Cat.#163-2016, Bio-Rad, USA) in 
accordance with the ReadyStrip™ IPG Strip instruction manual (Bio-Rad) for cup 
loading. The first dimension separations were performed by the PROTEAN ® IEF cell 
(Cat. #165-4000, Bio-Rad, USA) by the cup loading method. Equal amounts of each 
sample (400–600 µg) were loaded into the sample cups in the focus tray, and focusing 
was performed at 1000 V for 90 min (slow ramp), 3500 V for 90 min (slow ramp) and 
7000 V for 120 min (rapid ramp). 
 
For the second dimension-electrophoresis TRY 2DE, the focused IPG strips were 
equilibrated in a reduction buffer (37.5 mM Tris-HCl, pH 8.8, 6 M urea, 20% glycerol, 
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2% SDS, and 1% DTT) at 25°C for 15 min. The strip was then equilibrated in an 
alkylation buffer (37.5 mM Tris-HCl, pH 8.8, 6 M urea, 20% glycerol, 2% SDS, 
0.002% bromophenol blue, and 2.5% iodoacetamide) at 25°C for 15 min. The 
SDS-PAGE was performed in a 12% polyacrylamide gel cast in the Criterion® 3 Cell 
(Bio-Rad, USA) at 120 volt (V) during the first 15 min and at 200 V until the tracking 
dye reached the lower edge of the gel. Separated proteins were then 
electro-transblotted onto a nitrocellulose membrane for 2DE-immunoblotting. 
Chemiluminescent signals of AT1 receptors and actin were quantitatively detected 
using a Lumi-Imager. 
 
3.3.3. Animal Tissue Preparations 
All animal experiments were performed using Neph-hAT1R TGRs and age-matched 
wild-type (WT) littermates. The rats were maintained on a 12-h light-dark cycle with 
55% humidity at an ambient temperature of 23 ± 2°C and given free access to a 
standard pellet diet (Sniff, Soest, Germany) and tap water. Glomeruli and tubuli were 
isolated from rat kidneys by sequential sieving as described elsewhere.60 All studies 
were approved by the institutional animal care review committee and conducted 
according to the guiding principles of governmental authorities. 
 
 
3.4. Immunofluorecent Stainings 
The fluorescent antibody method, which is also known as the fluorescence-labeled 
antibody method and immunofluorescence staining, is an immunohistochemical 
staining technique that detects antigenic substances as markers of fluorescent anti-Ig 
antibodies based on the principle that clear fluorescence is observed against a dark 
background even when a fluorescent body is extremely small. This scheme can detect 
very small and distinct amounts of antigenic substances in renal tissue. 
 
When a substance is detected using the fluorescent antibody approach, the following 
two conditions must be met: the substance must be antigenic and specific antibodies 
must be produced in reaction to it; and, the antigenic substance must be insoluble in 
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tissue and present in a certain minimum amount (sensitivity) under stable conditions. 
 
3.4.1. Cultured Cells and Cortical F-actin Score Index 
Cells on coverslips were fixed in ice-cold trichloroacetic acid for 15 min (specifically 
for pERM and ERM protein staining) or 4% paraformaldehyde and 4% sucrose in PBS 
for 10 min at room temperature. Cells were permeabilized in 0.1% Triton X-100 for 10 
min at room temperature, blocked in 10% BSA in PBS for 1h and incubated with the 
phospho-ezrin(Thr567)/radixin(Thr564)/moesin(Thr558) antibody or 
ezrin/radixin/moesin antibody or α actinin-4 antibody followed by subsequent 
fluorophore-conjugated secondary antibodies and/or phalloidin (Alexa Fluor® 
488/594; Molecular Probes, USA) detection. Some cells were incubated briefly in 
4'-6-Diamidino-2-phenylindole (DAPI) (Molecular Probes) for nuclei visualization. 
Images were acquired using an inverted fluorescent microscope (Axiovert 100; Zeiss, 
Germany). 
 
 
Fig. 3.4.1 The design of CFS index The extent of F-actin cytoskeletal reorganization for each 
individual cell was assessed and scored on a scale from 0 to 3 based on the degree of cortical F-actin 
formation. At minimum three independent experiments were performed, and over 600 cells were scored 
in each group. The CFS index for Ang II or vehicle-treated podocytes is the average score of cells 
counted ± SEM. 
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Three independent experiments were performed for cortical F-actin score (CFS) index 
determinations. Cells were fixed, permeablized and then stained with 
fluorophore-conjugated phalloidin and DAPI as described. Twelve low-magnification 
images (400×) were taken randomly from each group. All cells in these images were 
counted (by DAPI-stained nuclei) and individually scored according to the criteria 
defined in Fig. 3.4.1 (by phalloidin F-actin staining). At minimum 600 cells were 
examined in the 12 images from each group, and the CFS index was generated by 
averaging counted cells. 
 
3.4.2. Cryosectioned Human Kidney Tissues 
 
3.4.2.1. Tissue Preparation and Storage 
Immediately after removing the renal tissue, it was wrapped in saline gauze and then 
specimens were prepared using a scalpel. Immediately freezing the tissue for the 
fluorescence antibody method is essential; that is, freezing and embedding must be 
performed immediately after removing the tissue. First, optimum cutting temperature 
(OCT) compound was added to a level of roughly 1–2 mm in the aluminum container 
and the tissue was floated on top. Then additional OCT compound was added to a 
level of 5–6 mm. If necessary, the tissue specimen was moved to the center using a 
scalpel. The upper part of the aluminum foil container was held using Nan forceps 
and the lower one-third to one-fourth of the container was immersed in the 
acetone–dry ice solution for freezing and embedding. Freezing was complete just 
before the top surface of the OCT compound became completely opaque. The frozen 
tissue was maintained at −80°C; this tissue can be used for several years if placed in 
thick plastic bags and kept in a vacuum. Adequate records of tissue specimens were 
kept. Use of a tissue ledger facilitated further use of the stored tissue specimens. 
 
3.4.2.2. Thin-Sectioning of Renal Tissue (Fresh Cryosections) 
The tissue was thinly sectioned using a cryostat at −20°C. The block support in the 
cryostat was removed to cool before usage. The aluminum foil around the OCT 
compound block containing the renal tissue was removed and the block was placed in 
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the cryostat. The adhesive tape was removed from the aluminum foil and was stuck 
on the cryostat. After placing a small amount of the OCT compound on the block 
support, the block containing the renal tissue was immediately placed on the OTC 
compound on the block before it had hardened and pushed slightly downward such 
that the tissue was at the top of the block. A short time was waited and thin sectioning 
was started once the OTC compound hardened. The sections should be 3–4 pm thick. 
After preparing the thin sections, the samples were wrapped in fresh aluminum foil, 
and the foil was wrapped in adhesive tape from the cryostat to preserve the samples. 
The thin tissue sections were placed on a glass slide. When the sections were in the 
center of the glass slide, a circle was drawn around the sections using a waterproof 
pen to avoid excessive use of antibodies. 
 
3.4.2.3. Indirect Double-Staining Method 
First, glass slides with tissue specimens were air dried for 20–30 min at room 
temperature. To eliminate serum protein, the glass slides were placed in the staining 
basket and washed three times for 5 min each time with PBS. Bovine albumin 
solution (4%) in PBS was applied to block non-specific endogenous antigens for 30 
min. The PBS around the tissue on the glass slides was wiped off with a paper towel 
and the unlabeled primary antibodies (50–100 µl) were applied using a Pasteur pipette. 
The glass slide was placed in the staining box and reacted for 1 h at room temperature 
or overnight at 4°C. After washing 3 times with PBS for 5 min each time, the 
fluorophore-labeled secondary antibodies were applied and reacted in the same 
manner as primary antibodies. Aluminum foil was used as a light shield when a 
plastic container was utilized. The container was sealed to prevent tissue from drying 
out. After washing 3 times with PBS for 5 min each time, the specimen was mounted 
using a PD-PBS-glycerin solution, and the glass cover was attached for visualization 
under a fluorescent microscope (Axiovert 100, Zeiss, Germany). After mounting, the 
cover glass was sealed with colorless nail polish. 
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3.5. 2-D DIGE System and Proteomics 
Proteomics is the large-scale study of proteins, particularly their structures and 
functions. Proteomics is typically considered the next step after genomics in studying 
biological systems. Proteomics is significantly more complex than genomics; 
although an organism’s genome is generally constant, a proteome differs from cell to 
cell and constantly changes through biochemical interactions with the genome and 
environment. One organism can have radically different protein expressions in 
different parts of its body, different stages of its lifecycle and different environmental 
conditions. 
 
3.5.1. 2-D Electrophoresis and DIGE 
2-D electrophoresis is a powerful and widely utilized method for analyzing complex 
protein mixtures extracted from cells, tissues, or other biological samples. This 
technique separates proteins based on two independent characteristics in two discrete 
steps. The first-dimensional step, isoelectric focusing (IEF), separates proteins 
according to their isoelectric points (pI); the second-dimensional step, sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), separates proteins based on 
their molecular weights (MWs, relative molecular mass). Each spot on the resulting 
2-D gel potentially corresponds to a single protein species in the sample. Thousands of 
different proteins can thus be separated, and information such as protein pI, apparent 
MW, and the amount of each protein can be acquired. 
 
The 2-D DIGE method labels protein samples prior to 2DE, facilitating accurate 
analysis of differences in protein abundance between samples. Up to three different 
samples can be separated within the same 2-D gel. This technology is based on the 
specific properties of spectrally resolvable dyes that have been designed as both mass- 
and charge-matched CyDye DIGE Fluor dyes. Consequently, identical proteins labeled 
with each CyDye DIGE Fluor dye migrate to the same position on a 2-D gel. This 
ability to separate more than one sample on a single gel permits the inclusion of up to 
two samples and an internal standard (internal reference) in each gel. The internal 
standard is prepared by mixing equal amounts of each sample in the experiment and 
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adding this mixture to each gel. The CyDye DIGE Fluors dyes are size- and 
charge-matched, pH insensitive, spectrally resolvable, highly sensitive, bright and 
photostable. 
 
Figure 3.5.1 presents the main steps in the DIGE system workflow. (A) The lysates to 
be analyzed were labeled with the fluorescent CyDyes Cy3 and Cy5. Additionally, an 
internal standard was labeled with Cy2. (B) The labeled samples were mixed and then 
separated according to their isoelectric points (1st dimension) and molecular weight 
(2nd dimension) in one gel. (C) Decyder software was used to analyze differential 
expression level of proteins. Samples were normalized using the internal standard. (D) 
All differentially expressed proteins that were down- or up-regulated >1.5-fold were 
isolated (picked) from the gel and measured using matrix-assisted laser 
desorption/ionization time of flight mass spectrometer (MALDI-TOFMS). (E) Peptide 
mass fingerprint analysis utilized Mascot software. (F) A flowchart illustrates the 
experimental design for both analytical and preparative gel workflow. 
 
 
 
Fig. 3.5.1 Standard processes of 2-D DIGE and proteomics study 
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3.5.2. Methods for 2-D DIGE and Proteomic Analysis 
For two-dimensional polyacrylamide gel–based analysis, podocytes were harvested 
and homogenized in 2DE lysis buffer (7 M Urea, 2 M Thiourea, 4% CHAPS, and 30 
mM Tris) with a micro tissue grinder followed by 3 rounds of sonication (1 min) in an 
ice bath sonicator at 4°C. Lysates were allowed to rest on ice for 30 min and then 
centrifuged for 1 h at 16000g. Supernatant protein concentrations were determined as 
described previously. Protein pH was assessed and adjusted when the pH of the cell 
lysate was outside the desired range (optimal cell lysate pH is 8.5 for CyDye DIGE 
Fluor minimal dyes). 
 
The protein samples from vehicle–treated and Ang II–treated podocytes were labeled 
with Cy3- and Cy5-CyDye DIGE Fluor minimal dyes (GE Healthcare, country), 
respectively, for 30 min at 4°C. A pooled sample of vehicle–treated and Ang II–treated 
podocyte lysates was similarly labeled with Cy2-CyDye DIGE Fluor minimal dye for 
use as an internal control. Excess unlabeled CyDye was inactivated by adding 1 µl 10 
mM lysine to stop the reaction. 
 
The Cy3-, Cy5-, and Cy2-labeled samples (50 µg each) were mixed with 1% Bio-Lyte 
3-10 IPG buffer, 40 mM DTT, and 0.002% bromphenol blue, and isoelectrically 
focused on an immobilized pH-gradient strip (24 cm; pH 3–10, non-linear) with a 
PROTEAN IEF cell. Focusing was performed at 150 V for 3 h (rapid ramp), 300 V for 
3 h (rapid ramp), 1000 V for 6 h (slow ramp), 10000 V for 3 h (slow ramp) and 10000 
V for 5 h (rapid ramp) to reach approximately 80000 total voltage-hours for isoelectric 
focusing. 
 
After focusing, strips were equilibrated for 15 min in a solution containing 6 M urea, 
30% glycerol, 2% SDS, 50 mM Tris-HCl (pH 8.8), 0.002% bromphenol blue, and 
DTT (10 mg/mL) followed by a second 15-min equilibration with iodoacetamide (25 
mg/mL) instead of dithiothreitol. Strips were briefly rinsed in 1× PAGE buffer and 
applied to a 12% polyacrylamide gel for electrophoresis at a constant current (16 
mA/gel overnight or 72 mA/gel for 5 h). Samples were prepared and then 
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electrophoresed in triplicate. 
 
A Typhoon scanner in fluorescence mode (GE Healthcare) was utilized to obtain Cy3, 
Cy5, and Cy2 images of analytical gels at a resolution of 100 µm. Images were 
analyzed using DeCyder software (GE Healthcare) to identify protein spots exhibiting 
statistical significant change between groups with the Student’s t-test and ANOVA. 
Preparative gels (loaded to about 1 mg protein of lysate per gel) were then fixed in 
30% ethanol and 7.5% acetic acid for 2 h, followed by Coomassie staining overnight 
for total protein visualization. Identified proteins of interest were picked from 
preparative gels as gel plugs. Figure 3.5.2 presents one representative preparative gel 
loaded with AT1R podocyte lysate and stained with Coomassie. 
 
 
Fig 3.5.2 Coomassie was used to stain preparative gel for protein spot picking and further MS 
analysis Proteins with differential expression levels (proteins of interest) in the Ang II-treated podocyte 
proteomic study are marked in red circles. 
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After trypsin (GE Healthcare) digestion of gel plugs, peptides were extracted and 
analyzed with an UltraflexIII matrix-assisted laser desorption ionization-tandem 
time-of-flight mass spectrometer (MALDI-TOF/TOF MS; Bruker Daltonics, 
Germany), operating in reflection positive-ion mode. The Swiss-Prot database was 
searched with GPS Explorer software (Applied Biosystems) and the MASCOT search 
engine (Matrix Sciences) to identify peptide mass data acquired using 
MALDI-TOF/TOF MS. A peptide group was considered a positive match for a 
database protein when the confidence interval (CI) for the match, as determined by 
GPS Explorer, was at least 95% and when spot position on the two-dimensional gel 
reflected approximately the theoretical isoelectric point and molecular weight of the 
specified protein. The MASCOT scores >61 were considered significant (p < 0.05). 
 
 
3.6. Gene Silencing 
Gene silencing is a general term describing epigenetic gene regulation processes. The 
term gene silencing is typically utilized to describe the process of “switching off” a 
gene using a mechanism other than genetic modification. In other words, a gene that 
would be expressed (turned on) under normal circumstances is switched off by cell 
machinery. This process has recently been best illustrated via the application of RNA 
interference (RNAi) to functional genomics, which relies on the ability of 
double-stranded RNAs (dsRNAs), small interfering RNAs (siRNAs), or small hairpin 
RNAs to silence a target gene through specific destruction of that gene’s mRNA.120-122 
 
3.6.1. Mechanisms of RNA Interference 
Gene silencing by dsRNA was first observed in plant experiments. In the late 1980s 
and early 1990s, genetic experiments conducted on petunias yielded unpredicted 
results. Introducing numerous copies of a gene coding for a deep-purple color 
generated plants with white or patchy blossoms, not a dark hue as was expected.123;124 
The introduction of genes had silenced both themselves and the plant’s intrinsic 
color-coding genes. 
 
METHODS 
65 
 
At that time, using antisense oligonucleotides (ASOs), short single-stranded stretches 
of DNA or RNA with a sequence complementary to their target mRNA, was the 
state-of-the-art method for gene-silencing experiments. However, experimental results 
for petunias were not compatible with the mechanism of gene down-regulation by 
ASOs. 
 
The puzzling findings for color alteration in petunias following transfection remained 
unexplained for nearly a decade. In 1998, Fire et al. determined that injecting dsRNA 
into Caenorhabditis elegans resulted in potent gene silencing.120 The dsRNA, several 
hundred bases in length, not only caused significant gene silencing, but was clearly 
more active than the corresponding single-stranded antisense molecules; this study 
obtained a revolutionary finding in the molecular biology field. Since introduced 
dsRNA molecules interfered with target gene function, the process was termed ‘RNA 
interference’. 
 
These first mechanistic clues to RNAi machinery were obtained from experiments 
using Drosophila extracts. Briefly, RNAi is initiated by long stretches of dsRNA that 
undergo processing by an enzyme referred to as a Dicer (Fig. 3.6.1).125 The Dicer cuts 
long stretches of dsRNA into duplexes with 19 paired nucleotides and 2 nucleotide 
overhangs at both 3´ ends.126 These duplexes are called siRNA. The double-stranded 
siRNA then associates with the RNA-induced silencing complex (RISC), a fairly large 
(roughly 160 kDa) protein complex comprising Argonaute proteins as the catalytic 
core of this complex127. Within the RISC, the siRNA is unwound and the sense strand 
is removed for degradation by cellular nucleases. The antisense strand of the siRNA 
directs the RISC to the target an mRNA sequence, where it anneals complementarily 
by Watson-Crick base pairing. Finally, the target mRNA is degraded by RISC 
endonuclease activity.128 
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Fig. 3.6.1 The RNA interference pathway Long double-stranded RNA (dsRNA) or small hairpin 
RNA (shRNA) was processed by Dicer and formed a small interfering RNA (siRNA) that is associated 
with the RNA-induced silencing protein complex (RISC) and mediates target sequence specificity for 
subsequent mRNA cleavage. Rutz et al. Arthritis Res Ther 2004 
 
 
This mechanism is fundamentally different from post-transcriptional gene silencing 
by ASOs. Binding of ASOs to their target mRNA hinders protein translation either by 
steric hindrance of the ribosomal machinery or induction of mRNA degradation by 
ribonuclease H (Rnase H).129 Although gene silencing by ASOs was considered a 
reliable approach for targeted gene down-regulation in human cell cultures, RNAi was 
first studied in C. elegans and plants; whether this technique would work in 
mammalian cells remained unclear. In 2001, Tuschl et al. provided the first evidence 
that siRNAs mediate sequence-specific gene silencing in mammalian cells and that 
the dicing step can be bypassed via transfecting siRNA molecules into cells.121 Since, 
RNAi could be used to study, and perhaps even influence, the molecular basis of 
human disease. 
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Notably, RNAi represents an outstanding strategy for controlling gene expression. In 
contrast to other mRNA-targeting strategies, RNAi utilizes physiological 
gene-silencing machinery, which may account for the excellent potency of RNAi. 
 
3.6.2. Vector-Based SiRNA 
Using DNA vector-based siRNA technology, a small DNA insert (approximately 70 bp) 
encoding a short hairpin RNA targeting gene of interest is cloned into a commercially 
available vector. The vector containing the insert, which expresses the short hairpin 
RNA can be transfected into a cell. The hairpin RNA is rapidly processed by cellular 
machinery into 19–22 nt double-stranded RNA (dsRNA). Key features of vector-based 
siRNA are as follows: vector-based siRNA is delivered as a plasmid, which is more 
stable and easier to handle than synthetic dsRNA and allows one to obtain a stable cell 
line and observe the long-term effects of RNAi. 
 
However, one important issue must be addressed. Experimental results from synthetic 
dsRNA or the siRNA cassette cannot be completely transformed into a vector-based 
siRNA construct. The vector-based siRNA differs from synthetic siRNA oligos and 
siRNA cassettes. Although experimental results obtained with synthetic siRNA oligos 
or siRNA cassettes can suggest the most potent siRNA targets, experimental results 
cannot be duplicated in vector-based siRNA for unknown reasons. 
 
3.6.3. Retroviral SiRNA Vector 
The pRNA-TH1.4/Retro vectors contain elements that facilitate packaging of the 
siRNA construct into retroviral particles. These retroviral particles are then utilized to 
infect mammalian cells and cause them to express siRNA in host cells. The H1 
promoter is employed to drive siRNA expression. A small DNA insert (roughly 70–80 
bp) encoding a short hairpin RNA targeting the gene of interest can be cloned into this 
vector between the Mlu I and Xho I sites. This vector, derived from Murino sarcoma 
virus, is designed for mammalian transfection and carries a hygromycin resistance 
gene that can be used to establish a stable cell line. 
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3.6.4. Cloning SiRNA Insert into pRNA Vectors 
Order two oligos with cohesive Xho I and Mlu I sites. 
 
 
Fig. 3.6.4 Oligonucleotide sequences for vector-based short hairpin RNA 
(upper strand only shown). 
 
 
The oligos must be PAGE-purified oligos. The oligos were dissolved in water to 1 
µg/µl concentration. The two oligos were then annealed. A 20 µl annealing reaction 
was prepared as follows: 
Top-strand oligo, 1 µl 
Bottom-strand oligo, 1 µl 
20 x SSC, 1 µl 
Add H2O to a final volume of 20 µl 
 
The mixture was heated to 95°C for 10 min, then taken out and allowed to rest at room 
temperature for 1 h. The mixture was diluted to a final concentration of 40 ng/µl. The 
vector was cut with Mlu I and Xho I. A 1% agarose gel was used to purify the vector. 
The vector was ligated with the insert using T4 ligase (molar insert-to-vector ratio was 
3:1). 
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The ligation mixture was transformed into competent DH5α cells and plated on 
Luria-Bertani Medium (LB)-ampicillin plates. At least 15 clones were chosen and 
grown. MiniPreps from the culture were prepared and the plasmids cut with Xho I and 
Mlu I. A 3% gel was run to determine whether the plasmids have the insert and select 
positive clones. The positive clones were sequenced to verify the insert sequence. 
 
3.6.5. Producing Retroviral Particles and Infecting Cells 
The RNA short hairpin gene-containing virus was produced by co-transfecting 
HEK293 cells with three plasmids (2.5 µg pMD.G, 7.5 µg pMD. gag/pol and 10 µg 
pRNA-TH1.4/Retro-mPrdx2/SH1) using the calcium phosphate method. The 
following procedures are exactly the same as described in Section 3.2.3 (Retroviral 
Gene Delivery). 
 
 
3.7. Statistical Analysis 
All data are presented as means ± SEM unless specified otherwise. Group differences 
were tested by Student t-tests. More than two groups were compared by two-way 
ANOVA (SPSS, Chicago, IL, USA). Statistical significance was p < 0.05. 
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4. Results 
 
4.1. Establishment and Characterization of a Stable Ang II-Responsive Podocyte 
cell line 
 
Immortalized mouse podocytes in culture were not consistently responsive to Ang II 
with elevated intracellular calcium concentrations ([Ca2+]i). To elucidate AT1R 
signaling mechanisms, human AT1R was stably expressed in a murine podocyte cell 
line known to show dominant stress fiber formation.113 Stable human AT1R expression 
was verified by RT-PCR (Fig. 4.1.1), and Flag-tag immunoprecipitation (Fig. 4.1.2) 
and two-dimensional immunoblotting (Fig. 4.1.3). 
 
 
 
Fig. 4.1.1 RT-PCR of wild type and AT1R podocytes (a) The RT-PCR results show that Flag-tagged 
AT1R transgene was only expressed in transduced podocytes (AT1R cells) using Flag tag sequence 
containing primers. Endogenous GAPDH mRNAs were detected with the same reaction condition as 
that for the internal control. (b) Endogenous AT1R and AT2R mRNAs were detected in wild-type (WT) 
podocytes in the same reaction condition but with more PCR reaction cycles. RT+, reverse transcriptase 
added; RT-, H2O added in stead of reverse transcriptase; hAT1R, human AT1R; mAT1R, mouse AT1R; 
mAT2R, mouse AT2R; mGAPDH, mouse glyceraldehyde-3-phosphate dehydrogenase; bps, base pairs. 
 
 
Retroviral transduction of the human AT1R gene enables differentiated cultured 
podocytes to express additional AT1R (2.72 ± 0.37-fold increase) than wild-type cells 
(Fig. 4.1.3). Empty vector transducted cells were generated as controls. 
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Fig. 4.1.2 Immunoprecipitation of Flag-tagged hAT1R in cultured podocytes Flag-tagged hAT1R 
were only precipitated in stably transducted AT1R podocytes and transiently transfected Hek cells. 
Immunostaining of β-tubulin demonstrates that each lane was equally loaded. IP, immunoprecipitation; 
IB, immunoblotting. 
 
 
 
Fig. 4.1.3 Two-dimensional immunoblotting of wild type and AT1R podocytes Equal amounts of 
proteins (400–600 µg in each experiment) from differentiated cultured podocyte lysates were separated 
by two-dimensional electrophoresis followed by immunoblotting. Quantified signal intensities of AT1R 
representing spots (calibrated by signal intensity of actin) reveal that AT1R was increased 2.72 ± 
0.37-fold in stably transducted cells (AT1R podocytes) compared with that of wild type (WT) cells 
(mean ± SEM, n = 4, p < 0.01). The second bar shows the AT1R expression level as a ratio factored for 
the first bar. 
 
 
Intracellular Ca2+ measurements indicate that differentiated AT1R podocytes 
responded with a significant and reversible [Ca2+]i increase after 100 nM Ang II 
stimulation (Fig. 4.1.4 a). The Ang II–triggered [Ca2+]i increase was 
concentration-dependent (Fig. 4.1.4 b, lanes 1–5), steadily responsive (AT1R cells 
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versus wild-type cells) and was inhibited by pre-treatment with losartan, an 
AT1R-specific antagonist (Fig. 4.1.4 b, lane 6).  
 
Fig. 4.1.4 Intracellular Ca2+ measurements of wild-type and AT1R podocytes (a) Fluorescence 
recordings demonstrate the effects of Ang II on [Ca2+]i in AT1R podocytes (inomycin 1 µM was used to 
calibrate [Ca2+]i after experiments). (b) The plot summarizes experimental results for [Ca2+]i response 
of podocytes to different Ang II concentrations and losartan (200 nM). Wild type (WT) podocytes in 
culture were not consistently responsive to Ang II with elevated [Ca2+]i (lane 7). Parentheses above 
each bar: (number of positive responses/number of stimulations). 
 
 
Moreover, expression of Ang II type 2 receptors (AT2R), known to exert opposite 
effects on Ang II signaling,130 was up-regulated in AT1R podocytes accompanying 
increased AT1R expression (Fig. 4.1.5 a). Single stimulation of AT2R achieved by 
combined treatment (Ang II 100 nM and losartan 200 nM) suppressed AT2R 
expressions in AT1R podocytes (Fig. 4.1.5 b), indicating that Ang II modulates 
crosstalks between AT1Rs and AT2Rs. 
 
Fig. 4.1.5 AT2R in up-regulated in AT1R stably transduced podocytes in an Ang II-responsive 
manner Representative immunoblotting and quantitative analysis of AT2R in cultured AT1R podocytes 
treated with Ang II (100 nM), Ang II with losartan (200 nM) or vehicle for 24 h (n = 3). Signal 
intensity of each band was standardized by quantitative SYPRO Ruby gel stain to eliminate the effects 
of differential loading. Each bar represents protein expression levels as a ratio factored for the first bar 
(means ± SEM). WT, wild type cultured podocyte. 
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Therefore, we conclude that AT1R podocytes, which respond constantly with [Ca2+]i 
increases, comprise a novel and reliable cultured podocyte model for investigating 
Ang II signal mechanisms. 
 
4.2. Increased Rac-1 Expression in Cultured AT1R Podocytes and in Glomeruli 
of Neph-hAT1 TGRs 
 
Figure 4.2 a shows that cytosolic Rac-1 expression increased after treating 
differentiated cultured AT1R podocytes with Ang II (100 nM, n = 3). The effects of 
Ang II on Rac-1 expression were limited by pre-treating cells with losartan (200 nM). 
 
 
 
Fig. 4.2 Increased Rac-1 expression in cultured AT1R podocytes and in glomeruli of Neph-hAT1 
TGRs (a) Representative immunoblotting and quantitative analysis of Rac-1 in cultured AT1R 
podocytes treated with Ang II (100 nM), Ang II with losartan (200 nM) or vehicle for 24 h (n = 3). 
Signal intensity of each band was standardized by quantitative SYPRO Ruby gel stain to eliminate the 
effects of differential loading. Each bar represents protein expression levels as a ratio factored for the 
first bar (means ± SEM). (b) Representative immunoblotting and quantitative analysis of Rac-1 
expression in kidney tissues from 4-week-old Neph-hAT1 TGRs and age-matched littermates (WT rat). 
Glomerular expression of Rac-1 was significantly higher in Neph-hAT1 TGRs than in WT rats (1.44   
± 0.12-fold versus WT, n = 6, p < 0.01). Tubular Rac-1 expression levels in Neph-hAT1 TGRs and WT 
rats did not differ significantly. Glom, glomerulus; Tubu, tubule; WT, wild type. 
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To determine whether Rac-1 impacts the AT1R signaling of podocyte damage in vivo, 
the expression of Rac-1 was examined in glomeruli and tubuli from 4-week-old 
podocyte-specific Neph-hAT1 TGRs and WT rats.60 At 4 weeks, Neph-hAT1 TGRs 
and age-matched littermates were phenotypically indistinguishable and nonproteinuric. 
Figure 4.2 b presents Western blotting results. Glomerular Rac-1 expression in 
Neph-hAT1 TGRs was 1.44-fold that of WT rats, whereas glomerular Rac-1 
expression was not significantly altered in the tubuli of Neph-hAT1 TGRs (n = 6). 
 
4.3. Effects of Ang II on ROS Generation and Migration in Podocytes 
 
Analysis of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent 
oxidase activity demonstrate that differentiated cultured AT1R podocytes 
pre-stimulated with Ang II (100 nM, 24 hrs) produced more superoxide anions (O2.-) 
than those in the vehicle-treated group (Fig. 4.3.1). The ROS-activating effect of Ang 
II was suppressed by losartan (200 nM), implying that an AT1R-specific mechanism 
exists. 
 
 
 
Fig. 4.3 Effects of Ang II on ROS production in podocytes (a) Illustrated time-dependent ROS (O2
.-) 
production in cultured AT1R podocytes with different pre-stimuli; (b) Summary of relative change in 
total ROS production in cultured AT1R podocytes pre-stimulated with Ang II (100 nM), Ang II + 
losartan (200 nM) or vehicle for 24 h. The NADPH-dependent ROS production increased in Ang II 
pre-stimulated podocytes (100.6 ± 9.2 nmol O2
.-/mg protein/15 min versus the vehicle-treated group: 
78.0 ± 6.1 nmol O2
.-/mg protein/15min, p < 0.05). Losartan exhibited a significant inhibitory effect on 
Ang II-induced ROS production. 
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An in vitro wound healing (‘scratch’) assay of confluent AT1R cells reveals that Ang II 
(100 nM, 24 h) pre-treatment increased cell migration (Fig. 4.3.2 a). Losartan (200 nM) 
or SCH51344, a Rac-1 specific inhibitor (10 µM), or DMTU, a free radical scavenger 
(10 mM), significantly attenuated Ang II–induced cell migration. Pre-treating cells 
with PD123319, an AT2R specific inhibitor (200 nM), did not alter the Ang 
II–mediated increase in cell migration (all n = 12; Fig. 4.3.2 b). 
 
 
Fig. 4.3.2 Rac-1–mediated Ang II effects on cell migration in podocytes (a) The in vitro wound 
healing (‘scratch’) assay for assessing podocyte migration. Movement of differentiated AT1R podocytes 
in culture into the wound with the vehicle or Ang II (100 nM, 24 h) pre-treatments represents cell 
migration. (b) Mean values of cell migration, expressed as number of cells crossing a 1 mm wound 
border (cells/mm border ± SEM), were calculated at 24 h and 48 h after creating the wound (n = 12 for 
each group). Losartan (200 nM), PD123319 (200 nM), SCH51344 (10 µM), DMTU (10 mM), scale bar 
= 250 µm. 
 
 
4.4. Characterization and Quantification of Rac-1-Mediated Podocyte 
Cytoskeletal Reorganization in AT1R Signaling 
 
Cell imaging shows increased lamellipodium activity and membrane ruffles in Ang 
II–treated single podocytes (Fig. 4.4.1 a). Furthermore, fluorescence microscopy 
reveals features of Ang II–mediated cytoskeletal reorganization in podocytes, 
including cortical F-actin ring formation and stress fiber attenuation (Fig. 4.4.1 b). 
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Fig. 4.4.1 Life cell imaging and staining of AT1R podocytes (a) Time-lapse phase contrast imaging of 
differentiated AT1R podocytes in culture Ang II–treated (100 nM) cells revealed increased lamellipodia 
(arrowheads) and membrane ruffles (quotation marks). (b) F-actin cytoskeletal reorganizations triggered 
by Ang II (100 nM, 24 h) in sparsely cultivated AT1R podocytes stained with fluorescein-conjugated 
phalloidin. All scale bar = 50 µm. 
 
 
In confluent cultivated podocytes, an identical F-actin cytoskeletal rearrangement was 
identified following Ang II stimulation (Fig. 4.4.2). 
 
 
Fig. 4.4.2 Confluent cultivated AT1R podocytes revealed the same cytoskeletal change in response 
to Ang II stimulation Scale bar = 50 µm 
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A cortical F-actin score index (CFS index) (Fig. 3.4.1) was constructed to quantify the 
extent of cytoskeletal reorganization in cultured podocytes at varying Ang II 
concentrations. Figure 4.4.3a presents the concentration-response curve for the effects 
of Ang II on CFS index in AT1R podocytes (n = 3). 
 
 
 
Fig. 4.4.3 Ang II and ROS induced concentration-dependent cytoskeletal changes in AT1R 
podocytes (a-c) Degree of F-actin cytoskeletal reorganization for each individual cell was assessed with 
a score of 0 to 3 based on degree of cortical F-actin formation. At minimum three independent 
experiments were performed, and over 600 cells were scored in each group. The CFS index for Ang II– 
or vehicle-treated podocytes is presented as average score for cells counted ± SEM. In (c): Ang II, 100 
nM; losartan, 200 nM; PD123319, 200 nM; DMTU, 10 mM; SCH51344, 10 µM. 
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Like Ang II, ROS induced concentration-dependent cytoskeletal changes in AT1R 
podocytes (Fig. 4.4.3 b, n = 3). The inhibitory effects of losartan, DMTU and 
SCH51344 on Ang II–induced change to the CFS index indicates that Ang II–mediated 
cytoskeletal reorganization in podocytes was mediated by an AT1 receptor, ROS and 
Rac-1 (Fig. 4.4.3 c, n = 3). 
 
4.5. Rac-1 mediates Ang II–induced ERM protein phosphorylation 
 
ERM proteins are crucial components linking the cortical F-actin cytoskeleton to 
membrane proteins at the peripheries of cells.70 To elucidate the influences of ERM 
proteins on AT1R signaling pathways resulting on cytoskeletal reorganization in 
podocytes, Ang II–stimulated cultured AT1R podocytes were analyzed by 
immunofluorescent staining. Ang II induced threonine phosphorylation of ERM 
proteins, and localization of phosphorylated ERM (pERM) proteins existed primarily 
at the peripheries of AT1R podocytes (Fig. 4.5.1). The Rac-1 inhibitor SCH51344 
inhibited the effects of Ang II on ERM protein phosphorylation, demonstrating that 
cortically distributed pERM proteins are downstream effectors of Rac-1 and mediate 
F-actin reorganization during AT1R signaling (Fig. 4.5.1). 
 
Fig. 4.5.1 The immunostainings of pERM and ERM proteins in AT1R podocytes The pERM 
proteins were increased and predominantly localized on the peripheries of AT1R podocytes following 
Ang II treatment (100 nM), and SCH51344 (10 µM) inhibited these effects. The ERM protein staining 
results indicate that no distributional difference exists before and after Ang II treatment (n =3, scale bar 
= 50 µm). 
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Immunoblotting results confirmed that AT1R mediates Ang II–induced ERM protein 
phosphorylation (Fig. 4.5.2 a). Ang II (100 nM, 24 h)–induced ERM protein 
phosphorylation was suppressed by losartan (200 nM), SCH51344 (10 µM) and 
DMTU (10 mM), indicating that AT1R, Rac-1 activation and ROS production are 
essential to this process. Both the absolute amount of phosphorylated pERM protein 
and percentage of total phosphorylated ERM protein increased in Ang II–treated 
AT1R podocyte (Fig. 4.5.2 b, n = 3). 
 
 
Fig. 4.5.2 Rac-1 mediates Ang II–induced ERM protein phosphorylation in immunoblotting (a) 
Representative immunoblotting of pERM and ERM protein expression in cultured AT1R podocytes. 
Ang II, 100 nM, 24h; losartan, 200 nM; SCH51344, 10 µM; DMTU, 10 mM. (b) Quantitative analysis 
plots for expression levels of (i) pERM proteins, (ii) total ERM proteins and (iii) percentage of total 
ERM protein phosphorylated. Signal intensity of each band was standardized as described earlier, and 
each bar represents protein expression levels as a ratio factored for the first bar (n = 3). 
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In glomeruli of Neph-hAT1 TGRs, immunoblotting results demonstrate that both total 
and proportional phosphorylated ERM proteins were increased compared those of 
age-matched littermates (Fig. 4.5.3, n = 5). 
 
 
Fig. 4.5.3 pERM expression is increased in Neph-hAT1 TGR glomeruli (a) Representative 
immunoblotting of pERM and ERM protein expressions in kidney tissues from Neph-hAT1 TGRs and 
age-matched littermates (WT). (b) Quantitative analysis plots for expression level of (i) pERM proteins, 
(ii) total ERM proteins and (iii) percentage of total phosphorylated ERM protein. Signal intensity of 
each band was standardized as mentioned previously, and each bar represents protein expression levels 
as a ratio factored for the first bar (n = 5) 
 
 
To elucidate signaling mechanisms resulting in ERM phosphorylation by Ang II, the 
effects of different serine/threonine kinase inhibitors on ERM protein phosphorylation 
were investigated. Heparin (a potent G protein-coupled receptor kinase 2 (GRK2) 
inhibitor), and not Y27632 (Rho kinase inhibitor), SB203580 (p38 MAPK inhibitor) or 
calphostin C (pan protein kinase C inhibitor), abated ERM protein phosphorylation in 
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Ang II–treated podocytes (Fig. 4.5.4, n = 3). 
 
Fig. 4.5.4 Heparin inhibits ERM protein phosphorylation in AT1R signaling of podocytes 
Representative immunoblotting results for different signaling inhibitors after eliminating Ang 
II–induced ERM protein phosphorylation in cultured AT1R podocytes (n = 3). Y27632, 10 µM; 
SB203580, 10 µM; heparin, 10 µM; calphostin C, 0.1 µM. 
 
 
Moreover, heparin inhibited the effect of Ang II on F-actin cytoskeletal reorganization 
of podocytes (Fig. 4.5.5). 
 
 
Fig. 4.5.5 Heparin inhibits the effect of Ang II on F-actin cytoskeletal reorganization of podocytes 
The CFS index was used to quantify the canceling effects of heparin on Ang II (100 nM, 24 h)–induced 
F-actin cytoskeletal reorganizations. At least three independent experiments were performed, and >600 
cells were examined and scored for each group. 
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4.6. Alpha actinin-4 is down-regulated in Neph-hAT1 TGR glomeruli and Ang 
II–treated cultured podocytes 
 
The α actinin-4, encoded by the FSGS gene ACTN4,35 is an actin bundle cross-linker 
and is also required for normal podocyte adhesion.92 To explore further the 
mechanisms linking chronically increased AT1R signaling in podocytes and 
proteinuria, expression levels of α actinin-4 in Neph-hAT1 TGRs (Fig. 4.6.1 a) were 
determined. Glomerular expression of α actinin-4 increased more than 2-fold in 
4-week-old Neph-hAT1 TGRs (Fig. 4.6.1 b i: 2.18 ± 0.24 fold, 4-wk hAT1 TGR glom 
versus WT). Thereafter, decreased glomerular expression of α actinin-4 was detected 
in 15-week-old Neph-hAT1 TGRs that exhibited proteinuria (Fig. 4.6.1 b ii, 0.82 ± 
0.10 fold, 15-wk hAT1 TGR glom versus WT). 
 
 
Fig. 4.6.1 Alpha actinin-4 is down-regulated in Neph-hAT1 TGR glomeruli and Ang II–treated 
cultured podocytes (a) Representative immunoblotting results for α actinin-4 expression in kidney 
tissues from 4-week-old and 15-week-old Neph-hAT1 TGRs and age-matched littermates. (B) 
Quantitative analysis plots for expression levels of α actinin-4. Signal intensity of each band was 
standardized as previously mentioned, and each bar shows α actinin-4 expression levels as a ratio 
factored for the first bar (n = 5 for 4-week-old rats, n = 3 for 15-week-old rats). 
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Expression of α actinin-4 was also down-regulated in cultured AT1R podocytes after 
24-h treatment with Ang II (Fig. 4.6.2). Notably, SCH51344, Y27632, heparin, and not 
SB203580 nor calphostin C, suppressed the effects of Ang II on α actinin-4 expression 
in AT1R podocytes, implying that Rac-1 signaling, RhoA signaling and F-actin 
cytoskeletal reorganization, but neither P38MAPK nor protein kinase C, regulate α 
actinin-4 expression. 
 
 
Fig.4.6.2 Rac-1 signaling, RhoA signaling and F-actin cytoskeletal reorganization regulate alpha 
actinin-4 expression in AT1R podocytes (a) Representative immunoblotting results for α actinin-4 
expression in cultured AT1R podocytes treated with Ang II (100 nM, 24 h) combined with different 
inhibitors (SCH51344, 10 µM; Y27632, 10 µM; SB203580: 10 µM; heparin, 10 µM; calphostin C, 0.1 
µM). (b) Quantitative analysis plots for expression levels of α actinin-4 in AT1R podocytes with 
different treatments. Signal intensity of each band was standardized as mentioned previously, and each 
bar represents α actinin-4 expression levels as a ratio factored for the first bar (n = 3). 
 
 
Double immunostaining results demonstrate that the α actinin-4 staining of 
vehicle-treated podocytes was confined to F-actin stress fibers (indicated by 
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arrowheads) and focal adhesions at the ends of stress fibers (indicated by arrows) (Fig. 
4.6.3 a). Ang II (100 nM, 24 h) treatment induced a reduction in α actinin-4 staining, 
down-regulation of focal adhesions and redistributed α actinin-4 to the periphery of 
cells as focal complexes (indicated by stars). Using the focal adhesion kinase 
(FAK)-specific antibody to detect cell-matrix interactions (focal adhesions and focal 
complexes), this study confirmed further that Ang II induced a phenotypical change, 
shifting from a dynamic-stable state (focal adhesions associated with F-actin stress 
fibers) to a migratory state (focal complexes associated with membrane ruffles). (Fig. 
4.6.3 b) 
 
 
Fig. 4.6.3 Immunostaining of adhesion molecules in AT1R podocytes (a) Immunostaining results for 
α actinin-4 (green) and F-actin (red) in cultured AT1R podocytes. Although Ang II induced stress fiber 
attenuation in podocytes; the number of focal adhesions (indicated by arrowheads) was also decreased. 
Arrows the α actinin-4 staining, which is cross-linked with stress fibers. Stars: focal complexes. (b) 
Immunostaining of FAK (green) shows similar distribution pattern changes. Scale bar = 50 µm. 
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4.7. Slit Diaphragm Protein—Nephrin is Down-Regulated in AT1R signaling 
 
The expression level of a slit diaphragm protein, nephrin, was examined to investigate 
molecular correlations between proteinuric phenotype and podocyte cytoskeletal 
reorganizations in Neph-hAT1 TGRs. Glomerular expression of nephrin decreased 
40% in 4-week-old Neph-hAT1 TGRs (Figs. 4.7.1 a and b: 0.59 ± 0.01 fold, 4-wk 
hAT1 TGR glom versus WT). At 4 weeks, Neph-hAT1 TGRs and age-matched 
littermates are non-proteinuric and phenotypically indistinguishable. 
 
 
 
Fig. 4.7.1 Nephrin expression is down-regulated before proteinuria development in Neph-hAT1 
TGRs (a) Representative immunoblotting of nephrin expression in kidney tissues from 4-week-old 
Neph-hAT1 TGRs and age-matched littermates. (b) Quantitative analysis plots for nephrin expression. 
Signal intensity of each band was standardized as mentioned previously, and each bar shows nephrin 
expression levels as a ratio factored for the first bar (n = 3). 
 
 
Immunofluorescent staining results of nephrin in Ang II–treated cultured podocytes 
demonstrate significant distribution changes (Fig. 4.7.2). Expression of nephrin was 
down-regulated in cultured AT1R podocytes after 24-h Ang II treatment (Fig. 4.7.3). 
Notably, SCH51344, Y27632, and heparin, but not SB203580 or calphostin C, 
suppressed the effects of Ang II on nephrin expression in AT1R podocytes, suggesting 
that Rac-1 signaling, RhoA signaling and F-actin cytoskeletal reorganization, but not 
p38 MAPK or protein kinase C, regulate nephrin expression. 
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Fig. 4.7.2 Immunostaining of nephrin, F-actin and beta-tubulin in cultured AT1R podocytes 
While Ang II (100 nM, 24 h) induced F-actin cortical ring formation in podocytes, nephrin expression 
was decreased and distributed cortically. The β-tubulin cytoskeleton was also altered following Ang II 
stimulation. Scale bar = 50 µm. 
 
 
Fig. 4.7.3 Rac-1 signaling, RhoA signaling and F-actin cytoskeletal reorganization regulate 
nephrin expression in AT1R podocytes (a) Representative immunoblotting results for nephrin 
expression in cultured AT1R podocytes treated with Ang II (100 nM, 24 h) combined with different 
inhibitors (SCH51344, 10 µM; Y27632, 10 µM; SB203580, 10 µM; heparin, 10 µM; calphostin C, 0.1 
µM). (b) Quantitative analysis plots for expression levels of nephrin in AT1R podocytes with different 
treatments. Signal intensity of each band was standardized as mentioned previously, and each bar shows 
nephrin expression levels as a ratio factored for the first bar (n = 4). 
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4.8. Proteomics of Ang II–treated podocytes 
 
Proteomic analysis of Ang II–stimulated (100 nM, 24 h) cultured AT1R podocytes 
provides an overview of differential protein expression levels in AT1R signaling. With 
the EttanTM DIGE system, mass spectrometry and peptide fingerprinting, this study 
identified 22 proteins of interest that have significant differential expression (Table 
4.8.1). 
 
 
Master 
No. 
T-test Average 
Ratio 
Target protein GI 
number 
MS 
Status 
2434  3.0e‐006  2.10  Enolase 1, αnon‐neuron  gi|54673814  confirmed 
432  9.0e‐005  1.96  Eukaryotic translation elongation 
factor 2 
gi|74213791  confirmed 
1027  0.013  1.91  Methylcrotonoyl‐Coenzyme A 
carboxylase 2 (beta)   
gi|58865926  confirmed 
1425  0.0040  1.73  Phosphoglycerate kinase (PGK) 1  gi|80477474  confirmed 
822  0.0071  1.64  Transketolase  gi|11066098  confirmed 
826  0.0097  ‐1.60  Prosaposin  gi|74207912  uncertain 
1454  4.5e‐005  ‐1.61  Laminin receptor 1 (ribosomal protein 
SA) 
gi|38014840  confirmed 
127  0.00019  ‐1.62  Hypoxia up‐regulated 1 (homology 
with HSP70 protein) 
gi|31542333  confirmed 
417  0.00023  ‐1.62  Tumor rejection antigen gp96 
(homology with HSP90 protein) 
gi|74178174  confirmed 
1097  6.6e‐006  ‐1.65  Tubulin β2‐chain  gi|22165384  confirmed 
264  0.00044  ‐1.65  Damage‐specific DNA binding protein 
1   
gi|74138855  confirmed 
765  8.1e‐005  ‐1.66  FK506 binding protein 9  gi|20072768  confirmed 
1077  6.3e‐006  ‐1.67  Vimentin  gi|2078001  confirmed 
2251  0.00017  ‐1.69  Peroxiredoxin 2  gi|31560539  confirmed 
731  3.3e‐008  ‐1.69  FK506 binding protein 9  gi|20072768  confirmed 
1754  3.1e‐008  ‐1.71  G protein β‐2 subunit    gi|984551  confirmed 
1620  5.3e‐006  ‐1.82  SEC 13 related gene product  gi|29150272  confirmed 
1012  0.0005  ‐1.92  Calreticulin  gi|74200069  confirmed 
2129  4.1e‐008  1.63  Triosephosphate isomerase 1  gi|6678413  confirmed 
1026  3.3e‐007  ‐1.68  Protein disulfide‐isomerase  gi|14318713  confirmed 
1857  1.3e‐005  ‐1.62  Tropomyosin 4  gi|47894398  confirmed 
1621  8.2e‐006  ‐1.66  Tropomyosin 1, alpha‐isoform  gi|78000190  confirmed 
Av. Ratio : average ratio of Angiotensin II stimulated groups in comparison with vehicle treated groups   
Table 4.8.1 Summary of proteomic results for Ang II–stimulated AT1R stable-responsive 
podocytes 
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Table 4.8.2 presents a summary of results of a thorough literature survey and analysis 
of these proteins with functional groupings. Proteomic results demonstrate that 
cytosolic enzymes involved in glycolysis and mitochodria enzyme MCCC2 (defects in 
MCCC2 are the cause of a recessive disease 3-methylcrotonylglycinuria type II 131) are 
significantly up-regulated. Thus metabolic and energy consumption of podocytes may 
be increased following Ang II stimulation. However, proteomic analysis showed no 
up-regulated protein expression in protein biosynthesis, stress-responsive process or 
neo-synthesis of cytoskeleton-related proteins. Cytoskeleton rearrangements of 
differentiated podocytes after Ang II stimulation likely explain this high energy 
consumption identified by proteomics. 
 
 
 
Table 4.8.2 Functional grouping results of AT1R podocyte proteomics 
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4.9. Peroxiredoxin 2 is Down-Regulated in AT1R signaling 
 
Peroxiredoxins have recently received considerable attention as a new anti-oxidant 
enzyme.132 Peroxiredoxin 2 (Prx2) belongs to antioxidant families and is about 40% 
down-regulated based on proteomic analysis results for Ang II–treated podocytes (Fig. 
4.9.1). 
 
 
Fig. 4.9.1 2-D map of peroxiredoxin 2 analyzed using DeCyder software Proteomic map indicated 
the difference of Prx2 expression in AT1R podocytes treated with and without Ang II (100 nM, 24 h), 
and then the differential expression levels of Prx2 was confirmed statistically by a Student’s t-test and 
one-way ANOVA. Spots representing Prx2 are marked with pink circles. The 2-D Cydye maps of 
vehicle-treated AT1R podocytes (control group) are outlined in blue, and the Ang II–treated group maps 
are outlined in green. Three independently treated sample pairs were examined with 2DE at the same 
time to eliminate interference from instruments and handling. 
 
 
To validate Prx2 data, this study performed Western blot analysis of protein lysates 
from Ang II–treated cultured AT1R podocytes (Fig. 4.9.2), and glomeruli of 
Neph-hAT1 TGRs (Fig. 4.9.3). Little is known about the function of Prx2 in 
kidneys.133 Additionally, this work is the first to characterize Prx2 in podocytes. This 
study performed a detailed immunofluorescence microscopic analysis of Prx2 protein 
localization in the kidney. Double immunostaining with a podocyte-specific marker 
WT-1 and a Prx2-specific antibody indicate that podocytes express abundant levels of 
Prx2 in vivo. (Fig. 4.9.4) 
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Fig. 4.9.2 Representative immunoblotting of Prx2 and Prx1 in cultured podocytes Ang II induces 
down-regulated expression of Prx2, but not in Prx1, another isoform of the Prx family. Wild type 
podocytes (WT) were used as controls. (all n = 4) (a) The expression level of Prx2 was down-regulated 
in cultured AT1R podocytes after 24-h Ang II treatment. Losartan limited the effects of Ang II on Prx2 
down-regulation in AT1R podocytes, suggesting that AT1R mediates this effect. (b) Ang II treatment 
had no influence on the Prx1 expression level. Ang II, 100 nM, 24h; losartan, 200 nM. 
 
 
Fig. 4.9.3 Expression of Prx2 was down-regulated in Neph-hAT1 TGR glomeruli Representative 
immunoblotting of Prx2 and actin expression in kidney tissues from 4-week-old Neph-hAT1 TGRs and 
age-matched littermates (n = 3). Wild type (WT) mouse kidney lysates were used as a positive control 
for Prx2-specific antibody. 
 
 
Fig. 4.9.4 Immunofluorescence staining of Prx2 and WT-1 in human glomeruli Prx2 (green, left) 
and podocyte-specific marker WT-1 (Wilms tumor suppressor gene; red, middle) were stained. Merging 
both images (right) suggests co-localization of Prx2 and WT-1 signals at podocyte cell bodies and FPs. 
The bright green signals within capillary loops are from red blood cells. Bar = 50 µm. 
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4.10. Decreased Prx2 Expression Also Causes Oxidative-Mediated ERM protein 
phosphorylated in Podocytes 
 
To elucidate the effects of Prx2 down-regulation in AT1R signaling, siRNAs 
specifically designed for Prx2 were stably expressed in cultured murine podocytes. 
Sustained suppression of Prx2 expression was verified by immunoblotting (Figs. 
4.10.1 a and b). Retroviral transduction of human AT1R gene facilitates differentiated 
cultured podocytes to express less Prx2 (48 ± 8%, n = 6) than WT cells. Empty vector 
and scramble sequence siRNA transducted cells were utilized as controls. 
 
 
Fig 4.10.1 The Prx2 knockdown podocyte cell line created by the retroviral-vector-based siRNA 
method (a) With a short hairpin sequence (Sh3) targeting both human (hum) and mouse (mus) Prx2 
amino acid position from 559–577, Prx2 expression level decreased 52% in a cultured mouse podocyte 
cell line. Short hairpin 1 and 2 had no effects on Prx2 expression by Western blotting with a mouse 
monoclonal antibody that specifically detects Prx2. (b) Using an antibody that can recognize all 
2-cystine Prx isoforms (Prx1–5) further demonstrates the Prx2-specific knockdown with Sh3. Notably, 
Prx3 is 28Kd & distributed mainly in mitochondria, whereas Prx4 is a 31Kd secretory isoform. Neither 
Prx3 nor Prx4 are shown in this representative blotting. (c, d) Differentiated murine podocytes (wild 
type) in sparse (c) and confluent (d) cultured conditions, respectively. The cells exhibit an aborized 
phenotype and form cell-cell contacts at the monolayer confluence. (e) The Prx2 knockdown podocytes 
are morphologically generally spindle-shaped and show little cell-cell contact even at high culture 
density. 
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Differentiated Prx2 knockdown podocytes have a morphology that differs distinctly 
from that of control cells (Figs. 4.10.1 c–e). Prx2 knockdown podocytes are minimally 
aborized and have minimal cell-cell contacts. Moreover, differentiated Prx2 
knockdown podocytes exhibit substantial ROS activity, which represents the 
anti-oxidant function of Prx2 in podocytes (Fig. 4.10.2). 
 
 
Fig. 4.10.2 Intracellular oxidants/ROS of Prx2 knockdown podocytes were analyzed using DHE 
fluorescence staining Compared with control cells (a), Prx2 knockdown podocytes (b) had more 
reactive oxygen species activities; this effect was abolished by the free-radical scavenger DMTU (c). 
 
Compensatory up-regulated expression of catalase, another anti-oxidant protein, 
provides indirect evidence demonstrates oxidative stress with excess ROS in Prx2 
knockdown podocytes. Similar to the Ang II effect, ERM protein phosphorylation was 
also observed in vehicle-treated Prx2 knockdown podocytes compared with WT cells, 
indicating the occurrence of F-actin cytoskeletal reorganization in podocytes. (Fig. 
4.10.3). 
 
Fig. 4.10.3 Representative immunoblotting results for pERM and catalase expression in cultured 
podocytes The ERM proteins are more phosphorylated in Prx2 knockdown podocytes (Sh3) than in 
scramble siRNA (Sh1) transduced cells and WT podocytes. Additionally, catalase was up-regulated in 
Prx2 knockdown podocytes and compensated for increased oxidative status. (n = 2) 
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Combined these experimental results further confirm that ROS and the resultant 
oxidative stress have a central role in AT1R signaling. These effects are achieved 
either by activating Rac-1 to increase ROS production or by down-regulating 
anti-oxidant protein Prx2 to attenuate removal of ROS. 
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5. Discussion 
 
5.1. Establishing an In Vitro Model to Explore AT1R Signaling in Podocytes 
 
Substantial experimental and clinical evidence indicates that inhibiting Ang II and/or 
its receptor improves proteinuria and this benefit is independent of decreased blood 
pressure. Podocytes have a central role in the pathogenesis of proteinuric glomerular 
diseases and in progression of chronic renal failure.1 The Ang II type 1 (AT1) and type 
2 (AT2) receptors are expressed on podocytes, and their expression is elevated in the 
proteinuric state.130 Furthermore, transgenic rats with overexpressed human AT1Rs in 
podocytes develop protein leakage and structural podocyte damage that progresses to 
focal segmental glomerulosclerosis (FSGS).60 On a cellular level, Ang II increases 
cytosolic Ca2+ concentration and synthesis of VEGF and TGF-β, but decreases ZO-1 
and nephrin expression, resulting in podocyte injury, hypertrophy and apoptosis.10 
 
This study investigated the effects of Ang II on cytoskeletal rearrangement of 
podocytes using a novel cultured murine podocyte model with stable expression of 
functioning AT1Rs. This proposed model was developed because murine podocytes do 
not respond consistently to Ang II and because expression of Ang II receptors is 
increased in glomerular diseases. Although AT1R is not as robust as transient 
transfection methods, the expression level of AT1 receptors in AT1R podocytes 
increased only 2.7-fold compared with empty vector transducted or WT cells. 
However, this increase was adequate to generate a cell line that is stably responsive to 
Ang II. Similar to podocytes in vivo,58;59 differentiated AT1R podocytes in culture 
responded with a significant [Ca2+]i increase via nanomolar concentrations of Ang II. 
 
The principal advantage of this AT1R podocyte cell line is that it is a convenient 
experimental model for investigating AT1R and AT2R signaling mechanisms. 
Although functional expression of the renin-angiotensin system has been characterized 
in human cultured podocytes, these cells do not respond constantly to Ang II with 
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increased [Ca2+]i. Culture methods for cells outgrowing from sieved glomeruli can 
acquire primary podocytes that respond well to Ang II; however, limited cell numbers 
and mesangial cell contamination still impede further signaling investigations and 
large-scale proteomics study. Stable transduction of human AT1R to a 
well-characterized immortalized murine podocyte cell line overcame these problems. 
Additionally, the AT1R podocyte has all features of the origin cells—dominant F-actin 
stress fiber formation, stable expression of nephrin and abundant formation of cell-cell 
contact, possessing several features of in situ podocyte cell-cell contact. In 
combination with Neph-hAT1 TGRs (developed proteinuria and glomerular damage 
that progressed to FSGS) and this AT1R podocyte cell line, we generated an 
experimental system that contains both in vitro and in vivo models. 
 
5.2. The Vital Physiological and Pathophysiological Roles of Actin Cytoskeleton 
in Podocytes and Filtration Barrier 
 
Like smooth muscles that develop isometric force over a very wide range of cell 
lengths—which reflects “mechanical plasticity,”—podocytes tether the underlying 
glomerular basement membrane via bundles of actin filaments in FPs while lining the 
outer aspect of the capillary loop. Podocytes, together with smooth muscle-like 
mesangial cells on the opposite side of capillary loop, counteract extension force due 
to hydraulic glomerular filtration (Fig. 5.2). 
 
To adapt to varying filtration forces due to blood pressure change and retain 
glomerular capillary loops at a constant size and shape, the F-actin cytoskeleton of 
podocyte FPs should develop considerable plasticity. Plasticity is defined here as a 
persistent change in cell structure or function in response to an environmental change. 
Important environmental stimuli that trigger F-actin cytoskeleton plasticity encompass 
chemical (e.g., glucose, ROS, autacoids, and cytokines) and external mechanical 
signals (e.g., applied stress and strain). Both signals are likely transduced by ionic and 
protein kinase signaling cascades that alter gene expression patterns and induce 
changes in the cytoskeleton and contractile system. 
DISCUSSIONS 
96 
 
 
Fig. 5.2 Diagram of a single glomerular capillary The peripheral endothelial cell cytoplasm (green, E), 
which has pores through it, looks like a small string of sausages on a cross-sectional view. The visceral 
epithelial cells or podocytes (blue, Po), have foot processes (Fp) that contain F-actin cytoskeletal 
networks (red). The glomerular basement membrane does not completely enclose the lumen, but rather 
splays out over the mesangium to become the paramesangial basement membrane. This results in a 
functional gap in which materials from the capillary lumen or subendothelial zone (having passed 
through the endothelial pores) can directly enter the mesangium without traversing the basement 
membrane. Mesangial cells (pink, M) are concentrated between capillaries at the vascular pole of the 
corpuscle. Abundant contractile F-actin bundles allow mesangial cells to anchor capillary loops in the 
vascular stack or glomeruli. This figure is drawed by Hsu and is summarzied and modified from Kriz et 
al. Kidney Int. 1998; Pavenstädt et al. Physio Rev. 2003 and Meyrier A Nat Clin Pract Nephrol 2005 
 
 
Defining the signaling mechanisms and effector proteins mediating phenotypic and 
mechanical plasticity of F-actin cytoskeletons is important in podocyte biology and 
pathophysiology. Some signaling cascades that are likely prominent include 
calcium-dependent protein kinases, small GTPases (Rho, Rac, cdc42), Rho kinase, 
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protein kinase C (PKC), Src family tyrosine kinases, mitogen-activated protein (MAP) 
kinases, and p21 activated protein kinases (PAK). Many potential targets exist for 
these signaling cascades, including nuclear processes, metabolic pathways, and 
structural components of the cytoskeleton. 
 
A dynamic steady-state F-actin cytoskeleton organization is crucial for maintaining 
structural integrity of FPs and provides stability between cell-cell contacting SD and 
the cell-matrix contact of podocytes.1 The ensuing actin cytoskeletal rearrangement 
following injury to this specialized organization causes the stereotypical response of 
FP effacement.134;135 
 
This study demonstrates that AT1R signaling induces a ROS-mediated F-actin 
cytoskeletal reorganization and a migratory phenotype of podocytes. This 
reorganization is likely a physiological response to podocytes that counteracts the 
increasingly distending forces of the capillary wall and covers the enlarged capillary 
surfaces induced by intraglomerular renin-angiotensin system activation. However, 
the actin-based cytoskeleton network in podocyte FPs is linked to the GBM (the basal 
membrane domain (BMD), which is also known as the sole plate), the apical 
membrane domain (AMD), and SDs through different adaptor molecules (Fig. 1.3 a). 
Sustained or severe alternation of the F-actin cytoskeleton in FPs likely impairs 
podocyte stability and viability, and further impairs the structure of the SD causing 
filtration barrier failure (Fig. 1.1). 
 
5.3. Rac-1 Orchestrates AT1R Signaling on Podocyte Cytoskeletons via ROS 
Formation 
 
Using the AT1R podocyte cell model and the Neph-hAT1 TGRs, experimental data 
demonstrate increased Rac-1 expression after Ang II stimulation and in the early stage 
of podocyte injury in Neph-hAT1 TGRs. Similar to the experimental results for 
Neph-hAT1 TGRs, Rac-1 participates in the development of Ang II–induced cardiac 
hypertrophy.136 In an animal model of cardiac hypertrophy, treatment with Ang II 
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activates NADPH oxidase, increases ROS production, induces cardiac fetal gene 
expression, and results in increased left ventricular mass. All of these effects of Ang II 
on the heart occurred with similar changes in blood pressure and were decreased or 
absent in mutant mice with decreased cardiac expression of Rac1. Notably, ROS has 
also been implicated in podocyte injury and diabetic nephropathy.137;138 These 
experimental findings suggest that glomerular Rac-1 likely plays a pivotal role in 
development of proteinuria and FSGS in response to Ang II. 
 
The Rho GTPases, members of the Ras superfamily of small GTPases, are the key 
regulators of actin cytoskeleton organization62 and are composed of three subfamilies: 
Rho, Rac and CDC42. The Rho family also has various effectors in vascular cells and 
tissues. One Rho effector—Rho-kinase (ROCK)—has an important role in smooth 
muscle contraction. Additionally, various vasoactive factors stimulate RhoA and 
ROCK, resulting in enhanced vasoconstriction and migration of vascular smooth 
muscle cells. Therefore, small G-proteins are possible therapeutic targets in 
cardiovascular medicine. Three members of the Rac family (Ras-related C3 
botulinum toxin substrate) show a cell type-specific expression: Rac-2 is generally 
restricted to hematopoietic cells; and, Rac-3 is preferentially expressed in neurons.139 
Notably, Rac-1 exhibits a ubiquitous expressional pattern and controls membrane 
protrusion by inducing assembly of an actin filament meshwork at the cell periphery 
to generate lamellipodium and membrane ruffles, thereby triggering cell migration. 
Additionally, Rac-1 is a crucial component of NADPH oxidase, which mediates Ang 
II–induced ROS production.63-65;140;141 
 
Our experimental data demonstrate that Rac-1 mediates the Ang II–induced increase of 
ROS production, F-actin cytoskeletal rearrangements (i.e., cortical F-actin formation 
and stress fiber attenuation) and the switch to a migratory phenotypic in AT1R 
podocytes. In contrast to recent studies suggesting that RhoA maintains F-actin stress 
fibers of podocytes,142-144 Rac-1 seems to orchestrate an adaptive cellular response to 
physiological stress or injurious stimuli in AT1R signaling, especially in the F-actin 
cytoskeleton modulating mechanism. As Rac-1 controls Ang II signaling in podocytes, 
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Rac-1 inhibitors may be thus a potential therapeutic target for protecting podocytes 
from excess ROS generation and cytoskeletal rearrangement. 
 
5.4. “Rac and Rho” of AT1R Signaling in Podocytes? 
 
The opposing effects of Rac or Cdc42 and Rho may be a general feature of these 
GTPases. For neurons, Rac and Cdc42 may be under the control of chemoattractants, 
whereas Rho can be activated by chemorepellants, leading to either localized 
protrusion or retraction of the growth cone.145 In considering phagocytosis of 
macrophage, which is driven by reorganization of filamentous actin, this study 
identified two distinct mechanisms: Type I, which is used by the immunoglobulin 
receptor and mediated by Cdc42 and Rac; and, type II, which is utilized by the 
complement receptor and is mediated by Rho.146 Moreover, significant cross-talk 
exists between GTPases of the Ras and Rho subfamilies: Ras can activate Rac (hence, 
Ras induces lamellipodia); Cdc42 can activate Rac (hence, filopodia are intimately 
associated with lamellipodia); and, Rac can activate Rho (although in fibroblasts, this 
is a weak and delayed response).147 These observational results suggest that members 
of the Rho GTPase family are key regulatory molecules that link surface receptors to 
the organization of the actin cytoskeleton and likely act together. 
 
Our experimental data demonstrate that in F-actin cytoskeletal reorganization of 
podocytes, Rac has a dominant role in the Ang II–induced ROS-pERM-cortical actin 
ring effector axis. With an efficient ROCK inhibitor (Y27632, 10 µM) that inhibits 
Rho activity in cultured podocytes, Ang II–induced ERM phosphorylation cannot be 
eliminated even when the cell shapes were markedly altered by F-actin stress fiber 
breakdown. However, in contrast to regulation of F-actin cytoskeleton, Rac and Rho 
are both necessary in the Ang II–associated expression regulation of α actinin-4 and 
nephrin. These dual activating effects of Rac-1 and RhoA signaling (“Rac and Rho” 
effect) are illustrated by experimental results (Figs. 4.6.2 and 4.7.3), for SCH51344, 
Y27632, and heparin, but not for SB203580 or calphostin C, inhibited the effects of 
Ang II on α actinin-4 and nephrin expression in AT1R podocytes. Distinct from Ang 
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II–induced cytoskeletal reorganization, during which the Rac effect prevails, 
down-regulated expression of α actinin-4 and nephrin is an effect of Rac and Rho 
interplay. 
 
5.5. “PKC-independent Rac Activation” of AT1R Signaling in Podocytes 
 
In vascular smooth muscle cells, vasoconstrictors, growth factors, cytokines and 
mechanical stretching induce intracellular signal transduction involving small 
GTPases and MAPKs. For instance, Ang II and endothelin (ET) stimulate 
transactivation of the epidermal growth factor receptor (EGFR) through its own 
G-protein coupled receptors. This effect occurs through a metalloprotease, such as 
ADAM 17, that produces mature growth factors. Activation of select small GTPases 
and MAPKs causes vascular diseases (Fig. 5.5 a). 
 
 
 
Fig. 5.5 Ang II cell signaling: physiological and pathological effects in vascular smooth muscle 
cells Metha et al. Am J Physiol Cell Physiol 2007 
 
 
In this disease model, Ang II regulates vascular smooth muscle cell survival, growth, 
and hypertrophy. Via activation of PKC, Ang II activates NADPH oxidase, a principal 
source of cellular ROS with increased intracellular Ca2+. In turn, NADPH-derived 
ROSs activate the EGFR in a c-Src–dependent manner. Once activated, AT1R 
transactivates numerous tyrosine and nontyrosine kinase receptors in carrying out its 
DISCUSSIONS 
101 
 
pleiotrophic effects. Notably, Ang II mediates cell survival via p38 MAPK, and Akt 
(members of the serine/threonine-specific protein kinase family). Cell growth and 
hypertrophy are mediated by Ang II–mediated MAPKs, p38 MAPK, extracellular 
signal-regulated kinase (ERK) and C-Jun N-terminal kinases (JNK), and the Janus 
kinases (JAKs) and signal transducers and activators of transcription (STATs) pathway, 
all of which result in changes in cellular protein transcription. 
 
Ang II induces vascular smooth muscle cell contraction in a PKC-dependent manner 
(Fig. 5.5 b). Experimental results show that when activated by an agonist, AT1Rs 
couple to Gαq/11, Gα12/13, and Gβy complexes, which activate downstream effectors, 
including phospholipase C (PLC), phospholipase A2 (PLA2), and phospholipase D 
(PLD). Activation of PLC generates inositol-1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG) within seconds. The IP3 binds to its receptor on the sarcoplasmic 
reticulum, opening a channel that allows calcium efflux into the cytoplasm, and Ca2+ 
binds to calmodulin and activates the myosin light chain kinase (MLCK), which 
phosphorylates the myosin light chain and enhances interaction between actin and 
myosin, causing smooth muscle cell contraction. Diacylglycerol activates PKC, which 
not only increases pH during cell contraction by phosphorylating Na+/H+ pump, but 
also participates as an effector in the Ras/Raf/MEK/ERK pathway (Fig. 5.5 a). 
 
This experimental study identified a PKC-independent AT1R signaling pathway for 
Rac-1 activation in podocyte cytoskeletal reorganizations. By using a sufficient 
concentration of pan-PKC inhibitors (calphostin C or tamoxifen), PKC inhibitors did 
not eliminate Ang II effects on ERM protein phosphorylation, indicating that Rac-1 
activation mediated cytoskeletal reorganization in cultured podocytes. Moreover, PKC 
inhibition augmented phosphorylation of ERM proteins in response to Ang II 
stimulation (Fig 4.5.4). Although ERM proteins are PKC substrates in several different 
cell types,148-150 experimental findings are consistent with a recent in vitro study 
demonstrating that activation of PKC suppressed phosphorylation of ezrin and moesin 
in carcinosarcoma cells.151 The mechanism of PKC’s augmentative effect remains 
unknown, but may be explained by feedback inhibition of G protein-coupled receptor 
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kinase 2 (GRK2) activity by ERKs,152 which are activated by PKC. 
 
A very recent experimental study demonstrated that ADP-ribosylation factor 6 (ARF6) 
and Rac-1 are sequentially activated when HEK 293 cells expressing the AT1R are 
stimulated with Ang II.153 Following receptor activation, ARF6 and Rac-1 transiently 
form a complex; this complex then induces AT1R expressing HEK293 cells to ruffle, 
form membranous protrusions, and migrate in response to agonist treatment. These 
experimental results also suggest that a novel PKC-independent Rac-1 activating 
mechanism in AT1R signaling leads to actin remodeling. 
 
5.6. Effects of Ang II–induced ROS on the Podocyte Cytoskeleton 
 
In vivo infusion of Ang II elevates blood pressure and generates ROSs in rat aortic 
rings.154;155 Oxidative stress resulting from Ang II and NADPH oxidase machinery is 
believed responsible for this Ang II-induced hypertensive effect. Oxidative stress is an 
imbalance between ROSs generation and scavenging such as superoxide anions or 
hydrogen peroxide (H2O2). Superoxide anions are metabolized by antioxidant proteins 
such as superoxide dismutases, catalases, glutathione peroxidases and peroxiredoxins. 
These ROSs are implicated in cell signaling and bioinactivation of nitric oxide, and 
contribute to aging, hypertension, and cardiovascular and kidney diseases. 
 
Reactive oxygen species are detrimental and toxic to cells and tissues as a result of 
injury to lipids, nucleic acids, and proteins. Lipid peroxidation of membranes causes a 
loss of membrane function, increases permeability and induces lipid autoperoxidation 
reactions. Notably, DNA damage results in mutation and cell death (apoptosis). 
Cross-linking or vulcanization of sulfhydryl-rich proteins causes signaling pathway 
dysfunction and stiff, aged proteins (specifically, collagen of the extracellular matrix). 
 
Sustained AT1R activation in podocytes cause excess ROS production, cellular 
oxidative stress, actin-binding molecule exhaustion, decreased focal adhesion and 
podocyte depletion, all of which can cause proteinuria. Recent experimental data 
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suggest that ROSs damage the F-actin cytoskeleton and impair the physiological 
function of different cells.156-158 
 
Our experimental results in this study demonstrate that ROS is a secondary messenger 
of AT1R signaling. Podocytes treated with Ang II (up to 10 µM) or low concentrations 
of superoxide anions (up to 5 µM) for 24 h did not cause cell necrosis or apoptosis. 
When using Ang II concentrations of 1–100 nM, which are very close to the typical 
physiological condition, and tiny amounts of superoxide anions (0.28–0.7 µM) to 
stimulate AT1R podocytes, cells present with membrane ruffles, lamellipodia and 
increased cell migrations. In addition to these Rac-1-specific effects, podocytes also 
developed F-acting cytoskeletal reorganization and ERM protein phosphorylation. The 
free radical scavenger DMTU eliminated Ang II–induced cell migration, ERM protein 
phosphorylation and cortical F-actin ring formation, demonstrating that ROS mediates 
the effects of Rac-1 on the migratory phenotypical switch, cytoskeletal reorganization 
(via ERM protein phosphorylation) and down-regulated α actinin-4 expression of 
podocytes. 
 
5.7. Effects of AT1R-induced Cytoskeleton Reorganization on the Apical 
Membrane Domain of FPs 
 
In the apical domain podocyte FPs, ezrin bridges the cytoplasmic domain of 
podocalyxin to the actin cytoskeleton through Na+/H+-exchanger regulatory factor 2 
(NHERF2).83 Podocalyxin, which is a heavy sialyated and sulfated membrane protein 
expressed on the apical surface of podocytes, functions as an antiadhesin that prevents 
cell-cell adhesion via charge repulsion as a result of abundant sialic acid residues, 
which give podocalyxin a highly negative charge. The association of the 
podocalyxin/NHERF2/ezrin complex with the F-actin cytoskeleton may anchor 
podocalyxin to specific microdomains of the apical membrane or determine its time 
residing on the cell surface. In damaged podocytes, the podocalyxin/NHERF2/ezrin 
complex is disrupted. Treatment of rats with puromycin or sialidase is associated with 
dephosphorylation of ezrin and uncoupling of ezrin from the cytoskeleton. These in 
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vivo findings suggest that a mechanism exists through which the loss of negative 
charge at the surface of podocytes alters FP morphology and stability of SD. 
 
Conversely, little is known about the process whereby excess phosphorylation of 
adapter molecules—the ERM family—target the F-actin cytoskeletal during podocyte 
injury. Structural changes between dormant and active conformations of ERM proteins 
are regulated by phosphorylation.70 Furthermore, phosphorylated ERM proteins are 
selectively found on cell surfaces and induce abundant formation of F-actin-membrane 
linkages.159;160 In studies based on cultured cells, Rho-kinase-mediated threonine 
phosphorylation in ezrin weakens intramolecular head-to-tail associations and 
unmasks membrane protein- and actin-binding sites. Once activated, ezrin generates 
its associations with plasma membrane proteins and the cortical actin 
cytoskeleton.13;161;162 In cultured endothelial cells, tumor necrosis factor 
(TNF)-alpha-induced ERM phosphorylation was accompanied by cytoskeletal changes, 
paracellular gap formation, and increased permeability to fluxes of dextran and 
albumin.148 
 
Phosphorylated ERM proteins, which may indicate a high F-actin turnover rate, are 
increased in Ang II–stimulated cultured podocytes and in glomeruli extracts of 
Neph-hAT1 TGRs. Both an AT1R blocker and a Rac-1 specific inhibitor, but not a 
Rho kinase inhibitor (Y27632, 10 µM 142;143), inhibit Ang II–induced F-actin 
cytoskeletal reorganization and ERM protein phosphorylations of cultured AT1R 
podocyte, indicating that, in contrast with studies of other cell types, RhoA does not 
predominantly mediate ERM protein phosphorylation in Ang II–stimulated podocytes. 
 
Regulation of ERM protein localization is not completely understood; however, the 
involvement of Rho GTPases is likely critical. A recent study based on cultured cells 
demonstrated that both Rho-dependent and Rho-independent activation of ERM 
proteins require the presence and local accumulation of phosphatidylinositol 
4,5-bisphosphate (PIP2) at the cell membrane destination and binding of PIP2 to the 
N-terminus of ERM proteins.163 Rho-independent ERM protein activation has been 
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demonstrated to be dependent on Rac-1 recruited phosphatidylinositol-4-phosphate 
5-kinase (PIP5K) activity, subsequently increased PIP2 production, and actin 
assembly.164 
 
The downstream kinase effector in podocyte AT1R signaling was elucidated by 
inhibiting serine/threonine kinases that have been reported using ERM proteins as 
substrates (i.e., Rho kinase,13;161;162 p38MAPK,148;165 G protein-coupled receptor 
kinase 2,166 and protein kinase C 148-150). Experimental data demonstrate that 
p38MAPK and protein kinase C do not phosphorylate ERM proteins in podocyte 
AT1R signaling. Notably, heparin, which has beneficial effects in proteinuric renal 
diseases,167 effectively eliminated Ang II–induced ERM protein phosphorylation and 
subsequently blocked rearrangement of the podocyte F-actin cytoskeleton. Heparin is 
well known as a potent inhibitor (IC50: 0.15 µM) of G protein-coupled receptor 
kinase 2 (GRK2).168-170 Furthermore, a recent study determined that ezrin is a novel 
substrate of GRK2-mediating membrane ruffles in Hep2 cells.171 Heparin may thus 
exhibit glomerular protection effects on the podocyte cytoskeleton by inhibiting 
GRK2-mediated ERM protein phosphorylation. 
 
5.8. Effects of AT1R Induced Cytoskeleton Reorganization on FP Basal 
Membrane Domain 
 
Mutations in the α actinin-4 gene (ACTN4) cause an autosomal dominant human 
kidney disease.35 Mice deficient in α actinin-4 develop a recessive phenotype 
characterized by kidney failure, proteinuria, retraction of glomerular podocyte FPs and 
FSGS.91 Both in vivo models appear to be nephron degenerated pathways with slowly 
progressing proteinuria and late onset glomerulosclerosis. Late onset diseases likely 
emerge from impaired functions of the podocyte cytoskeleton, whereas early onset 
diseases emerge from severe structure deficiencies of various components (GBM and 
the slit membrane). Loss of α actinin-4 depletes podocytes.92 Cross-linking of actin 
filament bundles by α actinin-4 is required for normal podocyte adhesion. Notably, α 
actinin-4 interacts with intergrins and strengthens podocyte-GBM interaction, thereby 
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stabilizing glomerular architecture and preventing podocyte detachment. Here we 
demonstrate that α actinin-4 expression is down-regulated in Ang II–treated podocytes. 
In Neph-hAT1 TGRs, decreased glomerular α actinin-4 expression was correlated with 
proteinuria development. Ang II–induced α actinin-4 down-regulation of podocytes 
was mediated by Rac-1, RhoA and pERM, demonstrating the importance of this 
signaling system for regulating α actinin-4 expression. Sustained Ang II signaling in 
podocytes, involving repeated depolymerization and polymerization of G-actins and 
consuming numerous actin adaptor or cross-linking proteins, may thus exhaust α 
actinin-4 expression and decrease the podocyte-matrix adhesion. Detachment of 
podocytes from the glomerular basement membrane causes gradual podocyte depletion 
and, finally, FSGS. 
 
5.9. Effects of AT1R Induced Cytoskeleton Reorganization on the SD Domain of 
FPs 
 
Neph-hAT1 TGRs start to develop proteinuria (selective albuminuria) at 8 weeks. 
Microscopic examination of the Neph-hAT1 TGR kidney revealed only mild 
pathological findings: 27% of glomeruli developed early podocyte lesions 
(pseudocysts) and the remaining glomeruli were without lesions. Under electron 
microscopy, morphology of the interdigitated FP is the same with Neph-hAT1 TGRs 
and WT rats. Moreover, pseudocyst formation is not a reasonable explanation for early 
onset proteinuria. 
 
Slit diaphragm dysfunction always induces proteinuria development. This study 
assessed expression of nephrin, a vital SD protein, in AT1R signaling. Like other 
podocyte injury factors, Ang II down-regulated nephrin expression in cultured AT1R 
podocytes and in 4-week-old Neph-hAT1 TGR glomeruli. Signaling pathway 
examination demonstrated that both Rac-1 activation and RhoA signaling are essential 
to regulating nephrin expression by Ang II. Furthermore, immunostaining of Ang 
II–treated podocytes showed that nephrin is redistributed in the cell-cell contact area in 
parallel with F-actin cortical ring formation. Recent in vitro and in vivo studies provide 
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compelling evidence that nephrin tyrosine phosphorylation controls podocyte cell 
morphology through Nck adaptor proteins.99;100 These experimental findings link 
nephrin to rearrangement of actin cytoskeleton in FPs and indicate that Nck adaptor 
proteins may mediate this connection. In a high actin turnover state in podocyte FPs, 
such as AT1R signaling activation, excess tyrosine phosphorylation may cluster 
nephrin with Nck adaptors and reorganized cortical F-actin filaments. This 
SD-associated molecule clustering may injure SD structure and result in FP 
effacement and proteinuria. 
 
5.10. AT1R Signaling Down-regulates Peroxiredoxin 2 in Podocytes—“RedOx 
Switching” 
 
Recent in experimental and clinical studies demonstrated that the Prx families are 
more than anti-oxidant proteins, but modulate many cellular processes by switching 
over the reductive-oxidative environment within cells. The identification of 
down-regulated Prx2 in Ang II–treated podocytes enables researchers to consider 
about ROS and oxidative stress in a manner that differs from conventional thinking. 
 
Like hydrogen peroxide or superoxide anions, ROS has been viewed for a long time as 
the inevitable but unwanted by-product of aerobic existence. Now researchers know 
that some cellular signaling is linked to reductive-oxidative-based mechanisms. For 
some specific signaling pathways, ROS is produced temporally and spatially to 
achieve the desired cellular outcomes. Figure 5.10 presents a summary of the 
production, protection and signaling of ROS. 
 
Notably, AT1R signaling in podocytes activates Rac-1 and NADPH oxidase to produce 
additional ROS, and down-regulates antioxidant protein Prx2 to maintain an oxidative 
environment that favors signal propagation. Prx2 knock-down podocytes showed an 
increased intracellular ROS activity and compensatory up-regulation of another 
antioxidant enzyme catalase. Cell morphology was also altered in Prx2 knock-down 
podocytes: reduced adhesion to the matrix, less aborization and loss of cell-cell contact 
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were observed. In addition, Prx2 knock-down causes phosphorylation of ERM 
proteins, which is indicative of high F-actin turnover status. Taken together, these 
experimental findings further indicate that Prx2 might be an important mediator of 
podocyte AT1R signaling. 
 
 
 
Fig. 5.10 ROS as a messenger for cell signaling Using H2O2 as a representation, ROS can be produced 
intracellularly or extracellularly by activating NADPH oxidase (Nox). Spatially produced H2O2 can 
modify the activity of key signal proteins—kinases and phosphatases. Notably, ROS catalyzing 
oxidation of essential cysteines eliminates phosphatase activities. Additionally, H2O2 promotes tyrosine 
phosphorylation by activating protein tyrosine kinases and creating an environment that favor proteins 
staying in the phosphorylated form. For H2O2 to serve as a signal—through modification of signaling 
proteins—its concentration must increase rapidly above a specific threshold. This can occur in the 
presence of temporarily inactivated antioxidant enzymes. During catalysis of H2O2 reduction, the 
active-site residue of Prx, Cys-SH, occasionally reacts with two molecules of H2O2 and, thus, becomes 
hyperoxidized to Cys-SOOH. Consequently, Prxs are inactivated. This inactivation, which can be 
reversed by sulfiredoxin, an adenosine triphosphate-dependent enzyme, likely represents a built-in 
mechanism that prevents suppression of the H2O2 signal. Ree SG Science 2006. 
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6. Conclusion 
 
By using the retroviral-based gene delivery method, a murine podocyte cell line 
(AT1R podocyte) stably expresses human AT1R and has a constant [Ca2+]i response to 
Ang II has been established. AT1R podocytes were a cell model for studying AT1R 
and AT2R signaling, and allowing performance of cellconsuming experiments. This 
study demonstrated that Ang II stimulation activities Rac signaling and up-regulates 
the expression of Rac-1 in AT1R podocytes. Ang II–stimulated podocytes revealed 
increased lamellipodia, membrane ruffles and cell migration — a cell phenotype 
typically directed by Rac-1. Elevated expression level of Rac-1 can also be confirmed 
in glomeruli of Neph-hAT1 TGRs that develop proteinuria, podocyte pseudocysts and 
finally focal segmental glomerular sclerosis. 
 
In podocytes, Ang II induced a Rac-1–mediated and ROS–dependent rearrangement of 
cortical F-actin, stress fiber attenuation and a migratory phenotype switch. The Ang 
II–induced actin cytoskeletal remodeling was promoted further by activated Rac-1 and 
phosphorylated ERM proteins. Phosphorylated ERM proteins indicate that the F-actin 
cytoskeleton in podocytes is in a high turnover state and can affect crucial podocyte 
molecules in either the apical domain, basal domain or SD of FPs. Heparin, a potent 
G-coupled protein kinase 2 inhibitor, eliminated ERM protein phosphorylation in Ang 
II–treated podocytes. However, inhibition of Rho kinase, p38MAPK or protein kinase 
C had no effect on phosphorylation. Moreover, Ang II signaling down regulated α 
actinin-4 and reduced focal adhesion expression in podocytes. Nephrin, a major 
molecule in the SD, was also down-regulated in Ang II-treated AT1R podocytes and in 
glomeruli of Neph-hAT1 TGRs. Similar to α actinin-4, expression regulation of Ang II 
on nephrin involves both Rac-1 and RhoA signaling. 
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Fig. 6 Integrated model of signal transduction via AT1R and resultant effects on podocyte 
cytoskeletons After using Ang II to stimulate AT1R in podocytes, Rac-1 GTPases were activated in a 
PKC-independent manner. Additionally, Rac-1 expression was elevated. Activated Rac-1 induced 
NADPH-dependent oxidases to increase production of ROSs. The AT1R signaling also down-regulates 
expression of peroxiredoxin 2, which is a newly discovered antioxidant enzyme and cellular redox 
reaction modulator. Increased cytosolic ROS transformed the cellular redox environment from 
reductive into oxidative. Activated Rac-1 and increased ROS caused ERM protein phosphorylation and 
membrane redistribution by activating GRK2. Phosphorylated ERM proteins promoted de novo F-actin 
synthesis at the periphery of cells and triggered F-actin cytoskeletal reorganization, i.e., cortical F-actin 
ring formation and stress fiber attenuation. In a Rac-1-dependent manner, RhoA signaling was also 
activated in AT1R signaling and mediated the reduction in α actinin-4 expression. A notable finding 
was that increased cell migration and the cell-matrix contact pattern shifted from focal adhesions to 
focal complexes, thereby supporting the hypothesis of a podocyte phenotype transformation. Migratory 
phenotype podocytes can exert an adaptive response to physiological or injurious events. However, 
long-term activation of AT1R signaling may have devastating effects on podocytes. This figure also 
shows that inhibitors exert definitive renoprotective effects (ACEI and AT1RB) or have therapeutic 
potential (Rac-1 inhibitor, SCH51344; antioxidants; and, heparin). 
 
 
AT1R signaling also down-regulates expression of Prx2, which is a newly discovered 
antioxidant enzyme and cellular redox reaction modulator. Using cultured Prx2 
knock-down podocytes, we observed more intracellular ROS activity and 
compensatory up-regulation of catalase. Cell morphology was also altered in Prx2 
knock-down podocytes: reduced adhesion to the matrix, less aborization and 
disruption of cell-cell contact. Increased cytosolic ROS transformed the cellular redox 
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environment from reductive into oxidative that favoring with phosphorylated ERM 
protein expression. 
 
Chronically activated AT1R may induce a sustained phenotype shifting from a 
dynamically stable phenotype to an adaptively migratory phenotype. Persisting 
cytoskeletal reorganization in the end may exhaust podocytes via a high actin 
cytoskeletal turnover, deplete podocytes and subsequently cause FSGS. These 
experimental findings also suggest that heparin and Rac-1 inhibitors may be 
therapeutic tools for treating podocyte injury. (Fig. 6) 
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7. Prospect 
 
The signaling mechanisms and cellular effects of Ang II–induced [Ca2+]i increase still 
remain unknown in podocytes. By using the complete experimental system that 
contains in vitro (AT1R podocyte cell line) and in vivo (Neph-hAT1 TGRs) models, 
the angiotensin signaling network in podocytes can be uncovered. How are the PKC 
isoforms, and MAPKs, as well as several tyrosine kinases (JAK, Src, FAK) involved 
in this pleiotropic signaling cascade in podocytes? What are the cellular responses to 
Ang II stimulation in cultured or in vivo podocytes (contraction, migration, cell 
survival, growth, hypertrophy, adhesion and extracellular matrix formation)? Some 
consequences of AT1R activation are counteracted by the structurally dissimilar AT2R, 
which antagonizes the effects of AT1R–mediated growth responses on several cell 
types. The results of AT2R actions in podocytes remain unclear. 
 
Proteins regulating the plasticity of the podocyte actin cytoskeleton are extremely 
important for maintenance of glomerular filter function. Podocyte cell shape changes, 
such as retraction of FPs, occur in minimal-change nephropathy, membranous 
nephropathy, focal segmental glomerulosclerosis, chronic glomerulonephritis, and 
diabetic nephropathy. What are the molecular mechanism orchestrate F-actin 
cytoskeleton reorganization in these clinical pathological entities? Heparin, a potent 
GRK2 inhibitor and exerting clinical therapeutic effects, may indicate the in vivo 
involvement of ERM protein phosphorylation in these proteinuric diseases. 
 
Small GTPases including Ras, Rho, Rac and their downstream MAPKs, including 
extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK) and 
p38MAPK, play central roles in cellular responses such as cell proliferation, apoptosis, 
migration and gene expression. Small GTPases act as molecular switches controlled 
by a GDP/GTP-binding cycle, thereby regulating gene expression, cytoskeletal 
reorganization, intracellular vesicle trafficking and microtubule organization during 
the cell cycle, and other signaling events. The mechanisms of how Ang II signaling, 
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oxidative stress, mechanical stress, vasoconstrictors and growth factors activate small 
GTPases in podocytes remain unclear. It is noteworthy that if these signal molecules 
are also significantly activated in glomerulus of Neph-hAT1 TGRs. Using specific 
small GTPase catalytic pathway inhibitors, the cellular effects of small GTPase in 
podocyte AT1R signaling can be investigated in both in vitro and in vivo experimental 
models. 
 
Recent clinical and experimental data demonstrate podocyte is the key player in 
diabetic nephropathy, the most frequent cause of end-stage renal disease. 
Podocytopenia is likely to be at the origin of proteinuria and segmental sclerosis in 
diabetic nephropathy. Podocyte loss has been reported in diabetic patients and many 
rodent experimental models. Notably, loss of podocytes is an early event in type 2 
diabetic patients and the number of podocytes is the only morphologic parameter 
which predicts disease progression. ACEIs and AT1RBs reduce proteinuria and 
moderate the decline in glomerular filtration rate in patients with diabetic renal disease. 
These clinical data imply that angiotensin signaling mediates injuries in diabetic 
podocytes. Preliminary data affiliated with this work showed ERM protein of cultured 
podocytes is extensively phosphorylated in a hyperglycemic environment. This 
pathophysiological implication of a high actin turnover rate in diabetic podocyte may 
correlate with sustained RAS activation The podocyte injury hypothesis and 
experimental findings of this work can be extended by investigating the role of RAS in 
the pathogenesis of diabetic nephropathy.
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